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ABSTRACT 
Drug delivery systems based on magnetic nanoparticles present a promising avenue for 
controlled targeted therapeutics, especially in cancer therapy. Conventional systematic 
therapeutics encompasses numerous side effects due to its limited selectivity between healthy 
and cancerous cells. In this thesis, novel polymeric-metallic hybrid nanoaggregates were 
developed to address this challenge. Magnetite nanoparticles were synthesized via 
precipitation of iron oxide and was surface modified using a unique chitosan derivative, 
glycol chitosan (GC), loaded with progesterone for potential hormonal therapy application 
for breast cancer. Surface characterizations techniques, in vitro drug release kinetics, 
investigation of progesterone release mechanism by mathematical modeling, and cell 
cytotoxicity were performed. In the size range of 10-20 nm, the synthetized nanoparticles 
with various GC compositions showed sustained progesterone release influenced by different 
polymer concentrations and found to be pH-responsive. The prepared nanoaggregates can be 
considered as a good potential for biocompatible controlled drug delivery applications.    
Keywords: Controlled drug release, superparamagnetic nanoparticles, iron oxide, glycol 
chitosan, drug delivery, mathematical modeling, polymer coating.  
 
 
 
 
 
 
 
 
 
 ii 
 
CO-AUTHORSHIP STATEMENT 
 
This thesis is an integrated article of two papers. The Review article is written in Chapter two 
and is accepted for publication. Chapter three is a research article in preparation for 
submission. 
Chapter 2 
Title: Bioactivity of Hybrid Polymeric-Magnetic Nanoparticles and Their Application in 
Drug Delivery.  
Authors: Leena Mohammed, Doaa Ragab, and Hassan Gomaa.  
Article Status: Accepted for publication in Journal of pharmaceutical Design. 
Leena extracted the most updated information and wrote the literature review. Doaa Ragab, a 
post-doctoral fellow, also contributed in writing a couple of sections in the paper. Dr. Gomaa, 
Leena and Doaa worked on editing and reviewing the manuscript prior to publication.  
 
Chapter 3 
Title: Synthesis and Characterization of Dual Stimuli Responsive Glycol Chitosan-Fe3O4 
Core-Shell Magnetic Nanoparticles for Controlled Drug Delivery of Progesterone 
Authors: Leena Mohammed, Doaa Ragab, and Hassan Gomaa, Shigang Lin, and Kibret 
Mequanint 
Article Status: In preparation for submission. 
 
This paper was supervised by Dr. Hassan Gomaa. Leena Mohammed conducted the 
experiments, analyzed data and wrote the manuscript of this paper. Doaa Ragab helped in 
conducting and writing the drug release experiment. A post-doctoral fellow under the 
supervision of Dr. Mequanint, Dr. Shigang Lin, preformed the in vitro cell study. Leena 
Mohammed, Doaa Ragab, and Dr. Hassan Gomaa contributed to the editing the manuscript.  
 
 iii 
 
ACKNOWLEDGMENTS 
First and foremost, I would like to deeply thank and Praise Allah, my God the Almighty, for 
his unlimited and continuous blessings and bounties. He showers me with strength, capability 
and patience throughout this academic journey of accomplishing the masters’ degree. 
I would like to sincerely acknowledge my supervisor, Dr. Hassan Gomaa, for his constant 
advice, guidance and continuous encouragement. He was always available for help despite 
his busy schedule and the long drive hours between cities to attend meetings and provide 
constructive supervision.  
I profoundly express my great appreciation to my lab mate, Doaa Ragab, for her ongoing 
advice, thoughtful criticism and motivation in enhancing my research. She is an intelligent, 
kindhearted individual who provided me with endless help, insightful ideas and valuable 
feedback since the first day of my study to the last. Moreover, I would like to acknowledge 
my colleague, Somiraa Said, for her assistance as well as Dr. Shigang Lin for his time and 
effort in conducting the cell study.  
Also, I would like to extend my wholehearted gratitude to my mother Selma, my father Laith 
and lovely siblings (Sara, Mariam and Saeed) for believing in my abilities and encouraging 
me to follow my goals in entering graduate studies.  Special thanks for my mother-in-law, 
Sumaya, and my friends Anfal and Um-Isra, for taking care of my daughter, Marya, during 
my studies.  
My indebtedness goes to my dear husband, Hatem Salim, for his confidence in me, and his 
persistent help all the way. I truly appreciate his charming support, unconditional love, care 
and understanding, which were much needed to achieve this success.   
 
 
 iv 
 
 
TABLE OF CONTENTS 
ABSTRACT .......................................................................................................................... i	  
CO-AUTHORSHIP STATEMENT.................................................................................... ii	  
ACKNOWLEDGMENTS ................................................................................................. iii	  
TABLE OF CONTENTS .................................................................................................... iv	  
LIST OF TABLES ........................................................................................................... viii	  
LIST OF FIGURES ............................................................................................................ ix	  
LIST OF SCHEMES .......................................................................................................... xi	  
LIST OF EQUATOINS .................................................................................................... xii	  
LIST OF SYMBOLS ........................................................................................................ xiv	  
LIST OF ABBREVIATION ............................................................................................. xvi	  
CHAPTER 1 ....................................................................................................................... 1	  
1 Introduction ....................................................................................................................... 1	  
1.1 The puzzling disease of our time- research motivation ............................................ 1	  
1.2 Nano-enabled drug delivery (NEDD) nanoparticles for breast cancer treatment ..... 2	  
1.2.1 Polymeric nanoparticles .................................................................................. 2	  
1.2.2 Lipid-based nanoparticles ............................................................................... 3	  
1.2.3 Noble metallic nanoparticles ........................................................................... 4	  
1.2.4 Magnetic nanoparticles ................................................................................... 5	  
1.3 Breast cancer treatment via hormonal therapy .......................................................... 7	  
1.5 Thesis hypothesis and Objectives ............................................................................. 7	  
1.6 Thesis outline ............................................................................................................ 8	  
1.7 References ................................................................................................................. 9	  
CHAPTER 2 ...................................................................................................................... 14	  
 v 
 
2 Bioactivity of hybrid polymeric-magnetic nanoparticles and their application in drug 
delivery .......................................................................................................................... 14	  
2.1 Abstract ................................................................................................................... 14	  
2.2 Introduction ............................................................................................................. 14	  
2.3 Physiochemical properties of magnetic nanoparticles ............................................ 17	  
2.3.1 Particle Size .................................................................................................. 18	  
2.3.2 Particles morphology .................................................................................... 19	  
2.3.3 Surface properties ......................................................................................... 20	  
2.3.4 Magnetic properties ...................................................................................... 21	  
2.4 Surface modification Exigency ............................................................................... 24	  
2.4.1 Colloidal Stability ......................................................................................... 24	  
2.4.2 Blood half-life and uptake by the reticulo-endothelial system (RES) .......... 25	  
2.4.3 Nano-cytotoxicity of hybrid polymeric-magnetic nanoparticles .................. 25	  
2.4.4 Oxidation resistance properties of hybrid polymeric- magnetic nanoparticles25	  
2.5 Polymer coating ...................................................................................................... 26	  
2.5.1 Natural polymers ........................................................................................... 27	  
2.5.2 Synthetic Polymers ....................................................................................... 31	  
2.6 MNPs in drug delivery and therapeutic platforms .................................................. 35	  
2.6.1 Chemotherapeutics agents ............................................................................ 35	  
2.6.2 Hyperthermia treatment ................................................................................ 38	  
2.6.3 Radio-therapeutic agent ................................................................................ 39	  
2.6.4 Gene Therapy and Magnetofection (MF) ..................................................... 39	  
2.6.5 Peptides/antibodies therapeutics ................................................................... 40	  
2.6.6 Hybrid magnetic nanoparticles for mitochondrial targeted anticancer drug 
delivery ...................................................................................................... 41	  
2.7 Routes of administration ......................................................................................... 42	  
2.7.1 Parenteral administration .............................................................................. 43	  
 vi 
 
2.7.2 Oral administration ....................................................................................... 43	  
2.7.3 Inhalatory administration .............................................................................. 44	  
2.8 Clinically approved SPIONs ................................................................................... 45	  
2.9 Industrial applications and scale up ........................................................................ 47	  
2.10 Mathematical models of drug release from hybrid polymeric-magnetic 
nanoparticles .......................................................................................................... 48	  
2.10.1 Korsmeyer–Peppas model .......................................................................... 52	  
2.10.2 The Huguchi model ..................................................................................... 52	  
2.10.3 Hixson–Crowell model ............................................................................... 53	  
2.10.4 First order model ......................................................................................... 54	  
2.10.5 Baker and Lonsdale ..................................................................................... 55	  
2.10.6 Weibull model ............................................................................................. 56	  
2.11 Conclusion ............................................................................................................ 57	  
2.12 References ............................................................................................................. 58	  
CHAPTER 3 ...................................................................................................................... 80	  
3 Synthesis and Characterization of Dual Stimuli Responsive Glycol Chitosan-Fe3O4 
Core-Shell Magnetic Nanoparticles for Controlled Delivery of Progesterone ............. 80	  
3.1 Graphical Abstract .................................................................................................. 80	  
3.3 Introduction ............................................................................................................. 82	  
3.4 Materials and Methods ............................................................................................ 85	  
3.4.1 Materials ....................................................................................................... 85	  
3.4.2 Synthesis of bare and GC-coated SPIONs .................................................... 86	  
3.4.3 Preparation of progesterone loaded GC-coated SPIONs .............................. 87	  
3.4.4 Magnetic and Structural characterization of bare and GC-coated SPIONs .. 87	  
3.4.5 Drug loading and encapsulation efficiency ................................................... 88	  
3.4.6 In-vitro cytotoxicity study of GC-coated SPIONs ........................................ 89	  
3.4.7 In-vitro release study of GC-coated SPIONs ................................................ 90	  
 vii 
 
3.6 Results and Discussion ............................................................................................ 91	  
3.6.1 X-ray Diffraction (XRD) .............................................................................. 91	  
3.6.2 Fourier transform infrared (FTIR) spectroscopy .......................................... 94	  
3.6.4 Scanning electron microscopy (SEM) .......................................................... 98	  
3.6.5 Thermo-Gravimetric Analysis (TGA) .......................................................... 99	  
3.6.6 Powder magnetization ................................................................................. 101	  
3.7 Evaluation of GC-SPIONs cytotoxicity ................................................................ 103	  
3.8 Progesterone loading and in-vitro Release ............................................................ 105	  
3.9 Study of the kinetics of progesterone release from glycol chitosan coated magnetic 
nanoparticles ........................................................................................................ 108	  
3.9.1 Investigation of the release behavior though various mathematical models109	  
3.10 Effect of pH change on progesterone release profile .......................................... 111	  
3.11 Conclusions ......................................................................................................... 113	  
3.12 References ........................................................................................................... 115	  
CHAPTER 4 ................................................................................................................... 122	  
Conclusion and recommendations…………………………………………………… ... 122	  
Curriculum Vitae………………………………………………….....…………….123 
 viii 
 
LIST OF TABLES 
Table 2-1: Summary of the recent advances in hybrid polymeric decorated magnetic 
nanoparticles and their potential biomedical applications………………………..………….18 
Table 2-2: The main clinically approved SPIONs in drug delivery………………………....44 
Table 2-3: Diffusional release mechanisms interpreted from a polymeric films according to 
exponent of release……………………………………………………..……………………51 
Table 3-1: Effect of the initial progesterone concentration (w/w) on the drug loading and 
encapsulation efficiency…………………………………….……………………………….88 
Table 3-2: Effect of GC concentration on the measured particle size data (TEM) and the 
calculated values based on XRD…………………………….………………………..……..92 
Table 3-3: Magnetization parameters of glycol chitosan coated magnetic nanoparticles 
compared to the bare magnetic core……………………..……………………………..…. 104 
Table 3-4:Release data containing encapsulation efficiency, loading rates and release rate 
constants for coated and uncoated SPIONs………..……………………………………….105 
Table 3-5: diffusional release mechanisms interpreted from polymeric films according to 
exponent of release…………………………………………………………………………108 
Table 3-6: Determination of the drug release mechanism based on the release exponent value 
of progesterone from SPIONs coated with different concentrations of glycol chitosan 
(GC)………………………………………………………………………………………...108 
Table 3-7: The empirical mathematical models used to fit progesterone release data……..109 
Table 3-8: Correlation coefficients values of fitted kinetic models on cumulative release 
curves on Fe3O4/GC………………..……………………………………………………….110  
 
 ix 
 
LIST OF FIGURES 
Figure 2-1: Alignment of magnetic moment of individual atoms of iron………..……….….21 
Figure 2-2: Magnetization curve of magnetic strength verses applied magnetic field 
...……………………………………………………………………………………..…...…..22 
Figure 2-3: Magnetic properties of ferromagnets dependence on particles' size……….....…23 
Figure 2-4: Polymers used in surface coating of SPIONs, sorted by their functional 
groups…………………………..…………………………………………………………….27 
Figure 2-5: Chemical structures of the main natural and synthetic polymers used in SPIONs 
coating………………………………………………………………………………………..34 
Figure 2-6: Graphical illustration of the various techniques of drug encapsulation in magnetic 
nanoparticles for targeted magnetic delivery…..……………………………….…………....48   
Figure 3-1: XRD pattern of Magnetite: (a) the effect of GC coating on the crystalline 
structure of SPIONs (b) standard XRD pattern of Magnetite……………..…………...…….92  
Figure 3-2: FTIR spectra of Glycol chitosan (GC), GC-coated magnetic nanoparticles, and 
uncoated magnetite…………………………………………………………….…………….94 
Figure 3-3: TEM images illustrating the effect of polymeric GC coating on bare SPIONs: (a) 
uncoated SPIONs (b) Fe3O4/GC-1 (c) Fe3O4/GC-2 (d) Fe3O4/GC-3…………………..….96 
Figure 3-4: Histogram of particle size distribution: A) for uncoated SPIONs with average 
size diameter of 8.76 nm and B) coated SPIONs with the middle used concentration of GC 
…………………………………………………………………………………….……….…97 
Figure 3-5: Scanning electron micrograph (SEM) images for different magnetic 
nanoaggregates. Effect of polymeric composition of GC on their morphology: a) uncoated 
SPIONs b) Fe3O4/GC-1 c) Fe3O4/GC-2 d) Fe3O4/GC-3……………..…………………....….98 
Figure 3-6: TGA profile of GC-coated magnetic nanoparticles and its first derivative 
graph……………………………………………………………………………………..…100 
 x 
 
Figure 3-7: Hysteresis curves at room temperature of bare and GC coated SPIONs……....101  
Figure 3-8: Dose-course of the metabolic activity of C3H 10T1/2 cells as determined by MTT 
assay………………………………………………………………………………………...103 
Figure 3-9: Time-course of the metabolic activity of C3H 10T1/2 cells as determined by MTT 
assay ………………………………………………………………………..……………....103 
Figure 3-10: Release profiles of progesterone from variable GC coated SPIONs formulations: 
effect of increasing GC surface coating on Fe3O4 at 5 mg progesterone……………..…….106 
Figure 3-11: The effect of pH value on the release profile of the highest concentration of GC 
coated SPIONs (Fe3O4/GC-3)…………………..…………………………………………..111   
 
 
  
 xi 
 
LIST OF SCHEMES 
Scheme 3-1: Chemical structure of chitosan (a) and glycol chitosan (b) …………...………83 
Scheme 3-2: Chemical structure of progesterone……………………………..……...……...84 
Scheme 3-3: An illustration of the in vitro release setup using dialysis system……….…….90 
Scheme 3-4: likelihood positions of H-bonding forming between glycol chitosan and 
progesterone…………………………………………………………………...……………106 
Scheme 3-5: An illustration for the proposed pH-responsive mechanism of Fe3O4-glycol 
chitosan hybrid magnetic nanoparticles………………………………………..…………...111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xii 
 
LIST OF EQUATOINS 
Equation 2-1: Calculation of particle size of the magnetic particle…………………….……23 
Equation 2-2: Calculation of drug transport of particle based on Fick's law of diffusion (first 
derivative) ………………………………………………………………..……………….…49 
Equation 2-3: Calculation of drug transport of particle based on Fick's law of diffusion 
(second derivative)…………………………………………………………..………….……49 
Equation 2-4: Calculation of the rate of drug release of Osmosis-controlled release…….…50 
Equation 2-5: Expression of peppas Model of drug release…………………………………51 
Equation 2-6: Expression of Huguchi model of drug release………………………….…….52 
Equation 2-7: Expression of Hixson–Crowell model of drug release……………………….52 
Equation 2-8: Modified equation of Hixson–Crowell model of drug release……………….52 
Equation 2-9: Expression of First order model of drug release………………………….…..53 
Equation 2-10: Modified equation of First order model of drug release…………………….53 
Equation 2-11: Baker and Lonsdale model of drug release………………………………….54 
Equation 2-12: Modified equation of Baker and Lonsdale model of drug release…………..54 
Equation 2-13: Simplified equation of Baker and Lonsdale model………………………….54 
Equation 2-14: Linear relationship of Baker and Lonsdale model…………………………..54 
Equation 2-15: Expression of Weibull model of drug release………………….……………55 
Equation 2-16: simplified expression of Weibull model of drug release……....……………55 
Equation 3-1: First chemical equation of the precipitation of iron oxide…………...……….85 
Equation 3-2: Second chemical equation of the precipitation of iron oxide………...……….85 
 xiii 
 
 
Equation 3-3: Third chemical equation of the precipitation of iron oxide………….……….85 
Equation 3-4: Calculation of drug encapsulation efficiency…………………………………87 
Equation 3-5: Calculation of drug loading percentage………………………………………88 
Equation 3-6: Calculation of the average particle size by Scherrer’s equation…………..….91 
Equation 3-7: Expression of the semi-empirical Korsmeyer- Peppas model….....………...107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiv 
 
LIST OF SYMBOLS 𝜀!              Initial porosity   - 𝑎               Scale parameter   - 
A              Cross sectional area      cm2 
b               Shape parameter - 
 c               Drug concentration      mg/ml 
C0             Drug initial concentration      mg/ml 
ci               Concentration of species i ,     mol/m3 
Cms            Drug solubility  mg/ml 
Cs              Concentration of drug in matrix bulk        mg/ml 
Ct              Concentration of drug in liquid layer surrounding membrane          mg/ml 
 D              Drug diffusion coefficient        m2/day  
dc/dt           Rate of change in drug concentration  mg/ml 
Dip             Represent the diffusion coefficient of species i       m2/s. 
Dm              Diffusion coefficient     m2/s 
ji                Mass flux of species i                                                                         mol/m2. s 
k                Boltzmann constant,                                                                    J/K  
K               Constant        - 
K               Drug specific volume                                                                   m3/ kg 
Ku              Universal axial anisotropy     erg/Cm 
Lp             Permeability coefficient        cm/day 
m              Accumulated drug released                                                                 mg/ml 
Mt/ M∞   fraction of drug released at time t       mg/day  
 xv 
 
Q               Cumulative amount of drug released     mg 
r               Particles radius                                                                                  nm 
r0                Radius of the matrix m 
t                Time     s 
T              Temperature   K 
Ti                Location parameter  - 
W0                    Initial amount of drug in a single dosage  mg 
Wt              Remaining amount of drug in a single dosage mg 
x               Position     m 
 β                Peak width                                                                              radians 
δ               Thickness of the device      µm 
δ or 𝜀         Porosity   - 
 Δπs           Osmotic pressure of water      atm  
θ                  Bragg diffraction angle  degrees 𝜅                Release rate constant                                                                  K/day  
 λ                X-ray wavelength   Å 
σ               Reflection coefficient         -  
 
 
 
  
 
 xvi 
 
LIST OF ABBREVIATION 
CKD                 Chronic kidney disease  
CLIOs              Cross-linked iron oxide  
CLSM               Confocal laser scanning microscopy  
CMS                  Carboxymethyl starch  
CTX                  Chlorotoxin  
DDS                  Drug delivery system  
DMBA              Dimethylbenz(a)anthracene  
DOX                  Doxorubicin  
ER                      Estrogen-mediated  
FDA                   Food and Drug Administration 
FITC                  Fluorescein isothiocyanate  
FTIR                  Fourier Transform Infrared  
GC                     Glycol chitosan  
GIT                    Gastrointestinal tract  
GNPs                  Gold nanoparticles  
GP                      Gamma probe  
GTA                   Glutaraldehyde  
HUVECs             Human Umbilical Vein Endothelian Cells  
IDA                     Iron deficiency anemia  
IONPs                 Iron oxide nanoparticles  
LHRH                 Luteinizing hormone releasing hormone  
MDT                   Magnetic drug targeting  
 xvii 
 
MEC                   Minimum effective concentration  
MF                     Gene Therapy and Magnetofection  
MFH                  Magnetic fluid hyperthermia  
MMP                 Matrix-metalloproteinase  
MNPs                Magnetic nanoparticles  
MRI                   Magnetic resonance imaging  
MS                     Manual magnetometer  
MSC                  Marrow derived stromal cells  
MTC                  Minimum toxic concentration  
MTX                  Methotrexate  
NEDD                Nano-enabled drug delivery 
NGPC                N-glycyrrhetinic acid-polyethylene glycol (PEG)-chitosan  
NPs                    Nanoparticles  
ODNs                 Oligodeoxynucleotides  
PAA                   Polyacrylic acid  
PCL                    Polycaprolactone  
PCL                    Polycaprolactone  
PEG                    Polyethylene glycol  
PEG                    Poly (ethylene glycol)  
PGD                    Poly(caprolactone) grafted dextran  
PLGA                  Poly(lactide-co-glycolide) 
PVA                    Poly (vinyl alcohol)  
PVP                     Poly (vinyl pyrrolidone)  
PVP                     Poly(vinyl pyrrolidone)  
 xviii 
 
RES                  Reticuloendothelial system  
SEM                  Scanning Electron Microscopy  
SLN                   Sentinel lymph nodes  
SLNs                 Solid lipid nanoparticles  
SPIONs             Superparamagnetic iron oxide nanoparticles   
TEM                  Transmission Electron Microscopy  
TEM                  Transmission electron microscopy  
TGA                  Thermo-Gravimetric Analysis  
Tmx                   Tamoxifen  
VB1                   Violamycine B1 
VSM                  Vibrating Sample Magnetometer 
XRD                   X-ray Diffraction  
1 
 
CHAPTER 1 
1 Introduction 
1.1 The puzzling disease of our time- research motivation  
Cancer is the second leading cause of death in the world and is expected to exceed heart 
disease as the top cause of death in the coming few years (1). In 2015, the number of cases 
diagnosed with cancer were 1,658,37 in the United States (1) and 196,900 in Canada (2). 
Approximately half of Canadians are expected to develop cancer in their life time and a 
quarter of these cases are expected to result in death (2). Among women, breast cancer is the 
most common type of cancer after lung cancer, with 68 Canadian women diagnosed with 
breast cancer every day, with a death rate of 14 women per day (3). In addition to the unclear 
causes of cancer, its treatment is exceptionally challenging and daunting.  The available 
therapeutics are one of or a combination of chemotherapy, radiation, and surgery, all of which 
are not guaranteed to be truly effective. Chemotherapy and radiation intend to destroy cancer 
cells yet have significant detrimental effects on active healthy cells. This is mainly due 
insufficient governing of cellular targeting, and if the cells of interest are targeted, the 
anticancer drug release rate is usually uncontrolled (4,5). However, the underlining difference 
between them is that radiation therapy results in localized damage to the radiated areas, while 
with chemotherapy side effects are systemic. In 20 studies including one quarter million 
women who had undergone radiation treatment worldwide, it was reported that the beneficial 
effects of radiotherapy in breast cancer women were offset by a 30% increase in heart disease-
death rate (6,7). On the other hand, surgery is an invasive approach that is not preferred by 
most breast cancer patients as it is accompanied by risks, complications and serious 
limitations. Frequently, patients express their willingness to be subjected to these treatments 
even if the expected survival rates are very low (8). Clearly, there is a desperate need for a 
much more effective breast cancer treatment in which a precise targeting of the affected tissue 
is achieved.  
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1.2 Nano-enabled drug delivery (NEDD) nanoparticles for breast 
cancer treatment  
Recently, the growth of nano-medical technology has burst mainly in the fields of 
nanopharmaceuticals and drug delivery. With both diverse and extensive research, it is quoted 
that targeted therapy represent one of the most promising options in breast cancer treatment. 
Nano-enabled drug delivery (NEDD) focuses on specific cell targeting and drug release 
strategies for direct administration to the needed site (9). This approach allows using a wide 
variety of therapeutics/drugs offering many advantages over conventional treatment methods. 
The main advantages are improved patient compliance, increased treatment efficacy, 
decreased toxic side effects, reduced dose, controlled biodistribution, and better drug 
localization (10).  The tailored NEDD systems nowadays in literature are extremely diverse. 
This includes but is not limited to: nanofibers, viral vectors, nanoparticles, hydrogels, 
quantum dots, nanocapsules, and carbon nanotubes (11,12). Not to mention, each of these 
systems has many subsystems and categories, which is beyond the scope of this thesis. Here, 
we will focus on the different kinds of nanoparticle systems, which are biomaterial aggregates 
in the size range of 1-100 nm (13).  
1.2.1 Polymeric nanoparticles 
In the field of oncology, there has been extensive research on chemically- modified polymeric 
nanocarrier systems due to their capability of carrying a wide range of drugs in a controlled 
manner for sustained period of time to tumor sites. They are advantageous over other 
nanoparticle systems, due to the ease of their preparation from well-understood polymers and 
have high stability in biological fluids as well as during storage (14). The fabrication of these 
systems is greatly dependent on their morphology and composition of the periphery and the 
core, hence, they are characterized by their physicochemical structures.  They include 
polymeric nanoparticles (NPs), dendrimers, polymeric micelles, polymersomes, polymer 
conjugate, polymer-lipid hybrid, and polyplex (15).  Polymeric NPs are solid colloidal 
systems in which the drug is entrapped, encapsulated, dissolved or absorbed into the natural or 
synthetic polymer matrix. Contingent to their design, they can form either nanosphere where 
drug molecules are bound to the surface or nanocapsules where drug is enclosed inside a 
polymeric membrane.(16,17). Various polymers such are poly(lactide-co-glycolide) (PLGA), 
chitosan, dextran, polyglycolide, polycaprolactone (PCL), and polyethylene glycol (PEG) 
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have been employed in fabrication of NPs and controlled targeting and release of cancer 
therapeutic agents. Using both passive and active targeting strategies, suppression of breast 
cancer cells were efficiently achieved (15). Among many examples, PLGA, an FDA approved 
biodegradable polymer, was applied in this regards. Tamoxifen (Tmx)-loaded PLGA 
nanoparticles (Tmx-NPs) were prepared via an emulsion diffusion evaporation method by Jain 
et al. (18), reporting an entrapment efficiency of over 85%. Oral antitumor efficacy in 12-
dimethylbenz(a)anthracene (DMBA) induced breast cancer model of Tmx-NPs was 
performed;  the tumor size was reduced to 41.56% compared with the control, untreated cells, 
where tumor size increased to more than 158.66%. Also, the targeting efficiency was proven, 
as hepatotoxicity was significantly less in comparison with free Tmx citrate as shown by 
histopathological examination of liver tissue. In another research study, poly(caprolactone) 
grafted dextran nanoparticles (PGD-NPs) were synthesised by modified oil/water emulsion 
method and were loaded with vinblastine as the anticancer drug (19). The fluorescent loaded 
PGD-NPs were tested in-vitro for cellular uptake and cancer cell viability using MCF-7 breast 
cancer cell line following their characterization and release study. Internalization efficiency of 
PGD copolymers was shown to be almost double in the MCF-7 group versus the control 
group (untreated cells). Lower viability rate of 50% was demonstrated after 48 h incubation 
mainly due to reduction in cell adhesive interactions in cells treated with drug-loaded NPs.  
1.2.2 Lipid-based nanoparticles  
Lipid-based nanoparticles are currently the most broadly investigated class of nanoparticles 
and are already in clinical use (20,21).  Their biocompatibility and ability to enhance drug 
bioavailability have made them suitable for drug delivery and cell targeting (22). Also, they 
bear the advantage of being the least toxic nanoparticle type in-vivo (23). They include 
Liposomes, micelles, solid lipid nanoparticles (SLNs), exosomes, and bolalipid vesicles (23). 
Xing et al. (24) developed liposomes functionalized with a 26-merguanosine-rich DNA 
aptamer AS1411 (a single stranded oligonucleotides with excellent targeting affinity specially 
to the nucleolin, an overexpressed protein in breast cancer). The functionalized liposomes 
were loaded with doxorubicin (DOX)- an anticancer drug. After testing both in vitro and in 
vivo, selective internalization was observed, with improved cytotoxicity to MCF-7 breast 
cancer cells and earlier tumor inhibition in mice bearing xenograft MCF-7 tumors. According 
to studies performed on SLNs, they have shown remarkable effects on MCF-7 cell line (25–
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27). The design of surface modified DOX-loaded SLNs using mannose was developed by Jain 
et al. (28), and its breast tumor targeting potential was investigated. Mannosylated SLNs 
demonstrated the highest cytotoxicity on MCF-7 cells compared to non-mannosylated SLNs 
and free DOX, where the ability to deliver a higher concentration of DOX with better 
internalization was achieved. Moreover, SLNs were established for the aim of decreasing 
breast cancer metastasis. Prepared via thin-film hydration method, these nanoparticles were 
coated with d-(alpha)-tocopheryl PEG 1000 succinate and phosphatidylcholine, and were 
loaded with Silibirin-an antimigratory agent for invasive tumors (29,30). According to the in-
vivo model results, 67% less pulmonary metastases formation and 39% less blood vessel 
metastases was reported compared to the saline-treated group. This can be attributed to the 
high efficiency and accumulation of silibinin-loaded SLNs taken-up by the MDA-MB-231 
breast cancer cells.  
1.2.3 Noble metallic nanoparticles  
Although lately research is employing noble metal nanoparticles as drug carriers in cancer 
therapy, its applications in the biomedical field existed since ancient time (31). Their 
effectiveness against numerous microorganisms and their efficacy in drug delivery was 
evident in several studies (32,33). One property that makes them attractive is surface stability. 
This allows their surface to be decorated with countless organic polymers and biological 
molecules serving as targeting agents and improving their efficiency. Dating many hundreds 
years back till today, gold, silver, and platinum nanoparticles are the most common. 
Interestingly, green silver nanoparticles (AgNPs) synthesized though leaf extract of 
Podophyllum hexandrum Royle under optimized conditions was reported (31,34). They have 
demonstrated the ability to selectively damage DNA and induce caspase-mediated cell death 
in breast and cervical carcinoma cells. Similar results regarding the effect of AgNPs on breast 
cancer cells were found in many studies (35,36). On another note, colloidal gold nanoparticles 
have been used widely due to their optical-electronic properties and high electron density, 
which can be applied in both diagnostic and therapy of breast cancer (37). Banu et al. (38) 
engineered folate conjugated polyethylene glycol gold nanoparticles (GNPs) loaded with 
DOX for folate receptor overexpressing breast cancers targeted treatment and combined it 
with photo-thermal therapy using laser. The efficacy of these particles was validated in vitro 
by their high internalization in MDA-MB-231 breast cancer cells with improved therapeutic 
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effects compared to plain DOX. However, it had lower effect on MCF-7 cell line since it 
expresses low levels of folate receptor compared to that of MDA-MB-231.  
1.2.4 Magnetic nanoparticles  
Magnetic nanoparticle are not only a well known category of nano-enabled drug delivery 
systems, they are also FDA approved and have been applied in many medical fields such as 
immunoassay, drug delivery, gene therapy, magnetic resonance imaging (MRI), tissue repair, 
cellular repairing, and biosensors (39). These particles posses a promising site-directed 
treatment using an external magnetic field. Decades ago, Frenkel and Dorfman speculated the 
ability of ferromagnetic particles to behave as super-paramagnetic at the nano-scale (40). This 
means that when the size of the particles are reduced below a critical point, they do not 
preserve any magnetism once the magnetic field is removed (41). This is the crucial factor that 
makes magnetic nanoparticles so distinctive. Theoretically, Superparamagnetic nanoparticles 
have no hysteresis, zero coercivity, zero remanence, much stronger magnetization, low 
particle agglomeration, and the ability to remain in the systemic circulation for long periods of 
time without being filtered out by natural mechanisms such as the immune system or though 
the liver. Beside particles size, chemical composition and the method of synthesis strongly 
affects the particles’ magnetic properties. Great efforts have been made to alter the chemical 
composition of nanoparticles’ core for the purpose of enhancing its magnetic properties. 
Metallic cores including Fe, Fept, FeCo alloys are the first to be investigated; however, their 
high toxicity and oxidation sensitivity in-vivo shifted the interest to ceramic cores, and 
specifically to metal oxides. Magnetic metal oxides provide boundless opportunities for super-
paramagnetic nanoparticles design with anticipated properties (42). Among the different types 
of metal oxides, magnetite (Fe3O4), is the most attractive owing to its high magnetic 
saturation, chemical stability, biodegradability, biocompatibility, ease of synthesis, non-
toxicity, relatively ease of functionalization, and low surface oxidation (43–46). 
Comprehensive literature had reviewed the different methods of iron oxide synthesis (47–49). 
They are categorized into three types: physical such as electron beam lithography and gas-
phase deposition; chemical such as chemical co-precipitation, hydrothermal reaction or 
thermal Deposition; and synthesis through microbial process (47). The method selected is 
based on the desired product and where it is going to be applied, as each method produce 
distinctive crystalline phase, shape, and size distribution of iron oxide nanoparticles (IONPs). 
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As it is fundamental to choose the appropriate core type and characterization of magnetic 
nanoparticle, coating its surface is equally important, yet challenging.  Providing a suitable 
coating later is a key aspect to promote the chemical and biological functionalization needed 
for bioselectivity and biocompatibility, consequently enhancing tissue and cell targeting 
effect. IONPs can be coated with organic materials using polymers, inorganic materials as 
gold and silica, or metal oxides such as aluminum oxide and titanium oxide (39). Also, they 
can be further functionalized using antibodies, small molecules, aptamer or peptieds, all of 
which are targeting ligands serving to decrease nonspecific distribution and to extend their 
blood circulation time in-vivo.  
Wide-ranging investigations on IONPs’ biological outcome and ability to target carcinoma 
cells, breast cancer more specifically, both in vitro and in vivo studies were performed. 
Among many examples, Marcu et al. (50) used laser pyrolysis method to synthesize IONPs in 
the range of 8–10 nm and found it to be better internalized in MCF-7 tumor cells’ cytoplasm 
and had lower anti-proliferation effects compared to commercial pure 20 nm IONPs. After 
further coating using antracyclinic antibiotic Violamycine B1(VB1), IONPs demonstrated a 
much effective VB1 delivery and cellular uptake verses free administrated VB1and 
commercial IONPs, respectively. In another study, IONPs functionalized with luteinizing 
hormone releasing hormone (LHRH) was demonstrated as promising tool for breast cancer 
cells targeting, as well as acting as contrast agent in MRI of breast cancer xenografts (51). 
Moreover, IONPs was applied and tested for detection of Sentinel lymph nodes (SLN) in 
breast cancer patients. SLN biopsy is a standard procedure used for the purpose of staging and 
diagnosis of breast cancer, whereas the combination of radioisotope and blue dye breast 
injection via gamma probe (GP) is commonly applied nowadays. Development of novel non-
radioactive method using IONPs and a manual magnetometer (MS) would be very promising. 
According to Piñero-Madrona et al. (52), the detection efficiency in 181 breast cancer patients 
were significantly indifferent for GP and MS methods, verifying IONPs diagnostic 
effectiveness in clinical trials. On another note, it was demonstrated that IONPs could be used 
as an effective candidate for separating circulating cancer cells in fresh whole blood. Human 
breast cancer cell SK-BR3 (HER2 positive) was used as a model cell by Xu et al. (53) to be 
captured by IONPs in fresh human blood. HER2 is a protein that is overexpressed in many 
types of cancer cells including breast cancer. The 30nm IONPs were coated with antibodies 
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against human epithelial growth receptor 2. These nanoparticles were able to separate 73.6% 
of SK-BR3 cells with an enrichment factor of 1:10,000,000 under magnetic field (cancer over 
normal cells).  
1.3 Breast cancer treatment via hormonal therapy 
The use of adjuvant hormonal therapy have assisted in increasing the survival rates in breast 
cancer women patients (54). An adjuvant therapy is a systematic anti-cancer therapy that is 
used often after surgery to destroy any remaining microscopic cancerous cells that might have 
been left behind. A adjuvant hormonal treatment of five to ten years was proven to reduce 
cancer recurrence risk by 50% in hormone responsive early breast cancer (55,56). About 80% 
of breast cancers are estrogen-receptors (ER) positive. In other words, they need estrogen to 
grow (57). This type of breast cancer produce either estrogen receptors or progesterone 
receptors or both, thus are named hormone-responsive. Currently, hormone therapies, or so-
called endocrine therapy, are effective in clinical use such as Tmx (an estrogen receptors 
blocker) (58). It is applied as adjuvant, non-adjuvant or in combination with other 
therapeutics, chemotherapy for example, depending on patient’s health circumstances. In a 
recent study (59), it was shown that the use of progesterone had suppressed estrogen-mediated 
growth of ER positive cell line and early ER positive breast cancer explants. It was also 
demonstrated that progesterone increased the anti-proliferation of these cells when combined 
with an ER antagonist. 
1.5 Thesis hypothesis and Objectives  
The main objective of this thesis was to develop superparamagnetic iron oxide nanoparticles  
(SPIONs) coated with novel soluble and biodegradable polymer (glycol chitosan) for 
application in hormonal therapy. Development of the controlled delivery system will be 
suitable for encapsulation of hydrophobic drug, progesterone. The fundamental hypothesis of 
this thesis is that the designed coated magnetic nanoparticles will be a promising drug carrier 
with enhanced bioavailability of progesterone to desired cells with sustained release 
depending on the concentration of glycol chitosan. This is achieved through studying the 
release kinetics of proposed surface modified SPIONs. Also, the release of progesterone 
mechanism is investigated using empirical mathematical under different reaction conditions. 
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Lastly, in-vitro studies were carried out to examine the biocompatibility of the synthesized 
nanoparticles.  
1.6 Thesis outline  
An investigation on a unique approach for designing magnetic nanoparticles is presented in 
this thesis. The proposed work focuses on progesterone as the therapeutic agent.   
Chapter one is an introduction to the thesis, where the motivation of research is presented. The 
common types of nanoparticle materials are discussed with a touch on the role of hormonal 
therapy in breast cancer treatment.  
Chapter two is a comprehensive review, which elaborates on the current studies performed on 
magnetic nanoparticles. It describes their physiochemical properties that allow their success as 
nano-drug carriers. This chapter discusses in detail the reasons of surface modification and the 
main important polymers used in current research. Their central applications in drug delivery 
are also presented with the commonly used mathematical models of drug release.  
Chapter three contains the research results described in detail. The magnetite (Fe3O4) 
nanoparticles were prepared for controlled delivery of progesterone through simple 
precipitation technique and then coated with new chitosan derivative that have never been 
used as a coat for IONPs nanoparticles in hormonal therapy applications.  Progesterone 
encapsulation and release was examined and mathematically modeled to study its release 
mechanism/kinetics.  
The conclusion and future prospects are outlined in chapter 4.  
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CHAPTER 2 
2 Bioactivity of hybrid polymeric-magnetic nanoparticles and 
their application in drug delivery 
2.1 Abstract  
Engineered magnetic nanoparticles (MNPs) possess unique properties and hold great potential 
in biomedicine and clinical applications. With their magnetic properties and their ability to 
work at the cellular and molecular level, MNPs have been applied both in-vitro and in-vivo in 
targeted drug delivery and imaging. Focusing on Iron Oxide Superparamagnetic nanoparticles 
(SPIONs), this paper elaborates on the recent advances in the development of hybrid 
polymeric-magnetic nanoparticles. Their main applications in drug delivery include 
Chemotherapeutics, Hyperthermia treatment, Radio-therapeutics, Gene delivary, and 
Biotheraputics. Physiochemical properties such as size, shape, surface and magnetic properties 
are key factors in determining their behavior. Additionally, tailoring SPIONs surface is often 
vital for desired cell targetting and improved efficiency. Polymer coating is specifically 
reviewed with a brief discussion of SPIONs administration routes. Commonly used drug 
release models for describing release mechanisms and the nanotoxicity aspects are also 
discussed.  
Keywords: Hybrid- magnetic nanoparticles; Iron oxide; Superparamagnetic; Drug delivery; 
Polymer coating; Biomedical applications; Mathematical modeling.   
2.2 Introduction  
“At the atomic level, we have new kinds of forces and new kinds of possibilities, new 
kinds of effects. The problems of manufacture and reproduction of materials will be quite 
different” (1). The father of nanotechnology, Richard Feynman, addressed these words more 
than five decades ago.  Since then, the inspiration of merging nanotechnology into clinical 
medicine had evolved. Nevertheless, recently nanotechnology research and development has 
been exponentially expanding, in both breadth and depth, like never before (2). 
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The interest in nanoscale materials as drug vehicles is mainly due to the need for change in 
conventional therapeutic strategies, particularly in delivery of highly toxic drugs such as in 
cancer therapy. Currently, the most commonly used conventional treatments are molecular or 
so called “free” drugs with systematic biodistribution. This encompasses many problems and 
adverse side effects primarily because of lack of specificity (1). Chemotherapeutics, for 
instance, attack both target and healthy cells due to its relatively poor specificity. Additional 
undesirable pharmacokinetics are present in molecular drugs including but not limited to: high 
dose admiration because of their rapid degradation in vivo, precipitation in aqueous solution as 
a result of their hydrophobic character, rapid clearance in biological body, and poor selectivity 
to target tissues (1). These issues along with other unfavorable properties existent in current 
treatments display great thrust to develop restricted drug delivery mechanism with high 
control at locoregional therapeutic level (3). The essence of optimizing drug nanocarriers is 
for i) directing drug to disease site with minimal side effects via reduction in systematic 
biodistribution of the cytotoxic drug and ii) reducing the dosage required through more 
localized and efficient targeting (4). Rising number of publications (5–7) have investigated 
how to engineer drug delivery system (DDS) nanocarriers which ideally should propose the 
following characteristics: 1) long body circulation, 2) specific targeting of disease site, 3) 
response to local stimuli in the pathological site such as abnormality in temperature, pH 
change or external magnetic field and/or heat, 4) enriched intracellular delivery of drugs or 
genes as required, 5) real time information of target accumulation and DDS biodistribution by 
carrying a contrast component (6). 
Among the enormous types of nanomaterial, MNPs are the most attractive due to their 
amazing physical characteristics and ability to function at both cellular and molecular level 
(1,2). The unique properties that magnetic colloids hold make them very suitable for 
biomedical applications. They have the capability of being visual under magnetic resonance 
imaging (MRI) as a mean for noninvasive imaging modality with high-resolution imaging and 
as contrast agents; and they have the promising means of transporting and maintaining at 
target site as therapeutic vehicle (8,9). There are two main methods in which magnetic DDS 
can function. First, through magnetic drug targeting (MDT) where an external magnetic field 
gradient is applied at target tissue. This mechanism is what makes MNPs distinctive. Second, 
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delivering through active targeting using ligand attachment of high affinity. Detailed 
explanation of delivery techniques is summarized later in this review. 
A major class of MNPs is iron oxides. They exist in sixteen pure phases in nature such as the 
oxides (magnetite and hematite), iron oxide beta phase and maghemite, hydroxides (iron (III) 
hydroxide or bernalite), oxy-hydroxides (geothite, akaganetite, lepidocrocite, feroxyhyte) and 
many others (10). One of their distinct characteristics includes low solubility, unique colors 
and having trivalent state (11). The most interesting and extensively studied type is the 
magnetite (Fe3O4). It is ferromagnetic black color iron oxide of both Fe (II) and Fe (III). 
Magnetite is the preferred type because of the presence of Fe2+ state with the potential of 
acting as electron donor. Also, it is relatively the most stable form in biological environment, 
as other forms like maghmeite and hematite produce free radicals which result in cell viability 
losses as more electron deficient Fe3+ are present (12,13). The structure of magnetite is an 
inverse spinel crystal with a face-centered cubic unit with edge length of 0.839 nm Fe2+ and 
half of the Fe3+ dominate the octahedral sites while the other half of Fe3+ dominates the 
tetrahedral sites and having 23 oxygen atoms (14).  
A unique type of magnetite is the superparamagnetic iron oxide nanoparticles (SPION). They 
gained most of research focus because of their many desirable features, most importantly: 
biocompatibility, biodegradability and ease of synthesis (2). The human body has a large iron 
pool (3 to 5 g) and a daily intake requirement of 20 to 25 mg (15). The amount of injection of 
treatment per person is comparable to the amount of daily intake (approximately 0.5 mg/kg) 
(15–17). Thus, biodegradable iron can blend with present body iron and participate in 
physiological iron homeostasis after drug release is accomplished at target cite (2,18). This 
biosafety represent one of the major advantages of SPION. In addition, their 
superparamagnetic nature makes them the most suitable type of MNPs for biomedical 
application. SPION leaves behind zero residual magnetization after an external magnetic field 
is removed (19). This property assists in avoiding coagulation, which consequently lowers the 
possibility of agglomeration in vivo compared to other MNPs (19).  
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2.3 Physiochemical properties of magnetic nanoparticles  
Physicochemical properties are extremely significant in determining the efficiency of targeted 
delivery. Same MNPs type with different physiochemical properties can potentially have 
completely altered pharmacokinetics, thus behaving differently in-vivo. Typically, MNPs have 
to overcome two biological barriers to reach the aimed target: physiological barrier and 
cellular barrier (1,15). The main properties that dictate their behavior in-vivo are size, shape, 
surface characteristic and its unique magnetic properties. SPIONs usually have two structural 
configurations: i) magnetic core (normally magnetite or Maghemite) with a biocompatible 
polymer coating on surface or ii) precipitate of SPIONs inside the pores of a highly porous 
biocompatible polymer (27). The coating act as a shield for SPIONs from surrounding 
environment where it aids to enhance targeting yield though improved properties and further 
surface functionalization (28,29). There are many SPIONs applications in biomedicine, the 
most known are considered in MRI as contrast agents (2, 30–33), and magnetic drug targeting 
or drug delivery as carriers of promising therapeutics (34–38). Table 2-1 summarizes the 
recent advances in hybrid polymeric decorated magnetic nanoparticles and their potential 
biomedical applications.  
This review will focus on superparamagnetic nanoparticles coated with different types of 
polymers. It will start with the key physiochemical features that dominate their behavior. The 
importance of surface modification will be addressed. Subsequently, the major classes of 
polymer modified iron oxide nanoparticles is demonstrated according to their clinical use and 
application. Clinically approved nanoparticles with a touch on scale-up and industrial 
applications are then addressed and the different routes of administration are mentioned. 
Lastly, mathematical models of drug release profile of the common used nanoparticles are 
addressed. 
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Table 2-1: Summary of the recent advances in hybrid polymeric decorated magnetic 
nanoparticles and their potential biomedical applications. 
 
2.3.1 Particle Size  
Particle size is the key determinant of the half-life of drug clearance in tissues (15). The main 
idea of using nanoscale versus macro-molecular drugs is to achieve a higher control residence 
time of drug release. Controlling the size is considered one of the most, if not the most, 
significant property in deciding particles fate. It must be chosen and formed with utmost care 
to ensure that it is small enough to avoid short blood circulation time via prompt splenic and 
liver filtration (smaller than 200nm), yet large enough to evade kidney filtration and rapid 
penetration (larger than 10 nm) (2,19–22). Predictably, particle size increases with surface 
modification as in coating and functionalization as it works hand in hand with MNPs chemical 
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composition. As blood vessels pore gaps can enlarge up to 400 to 800 nm during 
angiogenesis, size range for intervention administration of core MNPs should lie between 10 
to 100 nm, preferably between 20 to 60 nm for maximal cellular uptake (19,22,23).  
Size and size distribution can be controlled with method of synthesis. In coprecipitation, the 
most commonly used method, adjusting the pH and ionic strength of precipitation medium, 
particles mean size can be controlled over one order of magnitude (24,25). As pH and the 
ionic strength increases, the size decreases due to their effect on the surface chemical 
composition and thus particles electrostatic surface charge (24). Also, it has been shown that 
high- temperature decomposition of organometallic precursors can achieve higher control of 
size and size distribution (26,27). Changing the metal precursor or changing the reaction 
temperature can control nanoparticles size precisely. Using this method, Sun et al. showed that 
highly spherical Fe3O4 nanoparticles could be synthesized in the range of 4 to 20 nm with size 
variation of only 2nm. However, this process requires the use of oleic acid and oleylamine 
surfactants, which result in creating a hydrophobic coating on the nanoparticles. This demands 
an additional modification step to make it soluble in aqueous body fluid such as adding an 
amphiphilic polymer coating (28). Mostly SPIONs are applied as dispersed particles in 
aqueous medium. Even if mono-dispersed particles were achieved in synthesis, it can lead to 
greatly poly-dispersed aggregates in suspension due to hydrophobic-hydrophilic interactions, 
which creates new challenge of hydrodynamic size control (29,30). This is dealt with through 
critical choice of surface modification (30,31).  
2.3.2 Particles morphology 
Many studies have addressed MNPs shape and their magnetic properties and its effect on bio-
distribution and blood circulation time. However, most of the studies focused on spherical 
particles, while comparative investigations of non-spherical particles are lacking specially 
with regards to anisotropic configurations such as rode morphologies (32,33). This is due to 
the formation of one-dimensional (1-D) nano-ferrites, since spinel structure of iron oxide is 
highly symmetric (34). Nonetheless, recently there have been successful studies on synthesis 
of non-spherical particles such as cubic (35,36), rod (37,38), and hexagonal (39) shapes. 
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Alteration of chemical precipitation and coprecipitation method, nanoparticles shapes can be 
varied, yet it lacks shape control and size distribution. Yan et al. prepared nanosheets and 
nanowires with the addition of sodium acetate in co-precipitation of sulfate salts (40) . 
Thermal process had shown to produce a more precise and fine size control. Hyeon et al. (41) 
achieved a perfect cubic MNPs morphology by using Fe(acac)3 as precursor in benzyl ether 
and using oleic acid as a surfactant at 290 °C for 30 minutes. The reduction in benzyl ether 
allowed the alteration of truncated cubes and octahedral to very well defined cubic structure. 
Interestingly, it is shown that when chloride or bromide ions are lacking in the reaction, only 
spherical MNPs will be formed (42). In fact, it has been demonstrated that high control of 
shape towards cubic morphology is easily achieved by the presence of chlorine ions instead of 
controlling reaction thermo-kinetics (42,43). Recent report had descried the effectiveness of 
these iron oxide nano-cubes in hyperthermia treatment (44). Moreover, it has been shown that 
non-spherical nanoparticles avoid bio-elimination more efficiency than spherical ones. Several 
studies demonstrated the relationship between the increase in length to width ratio to longer 
the blood circulation times (45–48). Although these findings are promising, there is still a 
need for more studies on the effect of morphology on pharmacokinetics.  
2.3.3 Surface properties  
Surface property such as charge, hydrophobicity/hydrophilicity, smoothness/roughness are 
vital factors in determining nanoparticles capability as drug delivery vehicles, not only for 
biocompatibility and toxicity, but in determining particles biodistribution (49), cell adhesion 
on biomaterials (50–52), cellular interaction especially in endocytosis and phagocytosis (53), 
and blood half-life (54). In-vivo, MNPs surface interact with many elements including the 
immune system, extracellular matrices, plasma proteins and non-targeted cells. Positively 
charged MNPs can bind with non-targeted cells resulting in non-specific internalization (54) 
Osaka et al. studied the effect of surface charge on internalization on different cell lines (55).  
Compared to negatively charged surface, SPIONs with positive charge showed higher cellular 
uptake efficiency into breast cancer cells, yet no effect on Human Umbilical Vein Endothelian 
Cells (HUVECs). Therefore, SPIONs uptake efficiency depend not only on their surface 
properties but also on the body cell type. Specifically, hydrophobic and charged particles tend 
to be recognized by reticuloendothelial system (RES) quicker as a result of plasma protein 
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adsorption (opsonization), thus shorter circulation time (56). Moreover, hydrophobic particles 
are more susceptible to agglomeration leading to prompt RES removal (54). To limit MNPs 
host interactions, development of MNPs surface became essential. Many reports discussed the 
benefits of surface modification, which will be addressed in later sections.  
2.3.4 Magnetic properties   
Iron atom has a strong magnetic moment due to four unpaired electrons in its 3d orbitals. 
Different magnetic states occur when crystallization of iron occurs (Figure 2-1) (57,58) . The 
Paramagnetic crystal produces randomly aligned magnetic moments and overall structure has 
zero net magnetization. When paramagnetic state is subjected to an external magnetic field, 
moments will align producing a small net crystal magnetization.  At the ferromagnetic and 
antiferromagnetic states, the individual moments are aligned parallel and antiparallel 
respectfully without an external magnetic field. Ferromagnetic state however differ from 
antiferromagnetic in having two different types of atoms of different strengths (57).  
 
 
 
   
Paramagnetism        Ferromagnetism        Antiferromagnetism       Ferrimagnetism 
Figure 2-1: Alignment of magnetic moment of individual atoms of iron 
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Bulk ferromagnets contain several domains in which uniformly magnetized regions exist. 
Each domain is separated by non-uniform magnetization distributions (domain walls) with 
different magnetization vector. Since the vectors of each domain are not aligned, the net 
magnetization is lowered. As the size of material decreases, the number of domain decreases 
until there is one domain left below critical size diameter (usually <15-20 nm) which are 
superparamagnetic nanoparticles (57,59,60). 
Magnetization curve (Figure 2-2) illustrates the relation between applied external magnetic 
field with strength H, and magnetic strength M, which increases until a saturation value Ms is 
reached. Hysteresis loop is produced because the domains do not return to their original 
orientation when external field is removed and a saturation magnetization value (coercivity) is 
attained. This coercivity only vanishes after applying coercive field of strength Hc in the 
opposite direction.  In the case Superparamagnetic particles, no hysteresis is produced; a much 
stronger magnetization is present which is zeroed after the removal of external magnetic field 
(coercivity=0) (19,50,61,62). Curie temperature terms the transition temperature TC for a 
material to lose its permanent magnetic properties, while blocking temperature TB describes 
the temperature where usually superparamagnetic ordering exist (57). Particle size is very 
crucial for  
Figure 2-2: magnetization curve of magnetic strength M verses applied magnetic 
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superparamagnetic property to appear. Figure 2-3 shows the effect of particle size on 
magnetic property and is described by Eq. 2-1 (50).    
                                          𝒓 =    𝟔𝒌𝑻𝑲𝒖𝟑                                                     (Eq. 2-1) 
Where, r is particles radius, k, Boltzmann constant, T, temperature, and Ku the universal axial 
anisotropy.  
 
Fe3O4 is ferromagnetic and has a Tc of 850 K (63) and becomes superparamagnetic below 
critical diameter. It is important to note that magnetic properties depends strongly on the 
method of synthesis (64,65) and on crystal structure (66) even when particle size is similar. 
The presence of impurities disturbing the crystal structure during synthesis as well as the 
effect of surface properties described earlier result in magnetization alteration (2). The 
coercivity is strongest in octahedral shape followed by cubes and spherical morphology due to 
the increase in the number of magnetic axes of these shapes order (57,67).   
≥ 1 μm 
spontanous magnetization 
below Tc, nonzero 
magnetic moment 
formation of domain 
structure                                               
50 - 1000 nm
sample, synthysis and 
processing method 
dependent 
1- 30 nm 
T<TB magnetic hysteresis
T>TB 
superparamagnetization 
TB<T<Tc nonzero net 
magnetic moment 
~ 0.2 nm
usual paramegnetic 
properties
Figure 2-3- magnetic properties of ferromagnets dependence on particles' size 
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2.4 Surface modification Exigency 
Since the properties SPIONs are mostly surface dependent, surface chemistry plays a main 
role in changing its biological and physiochemical properties to a desired in-vivo application. 
There are two main methodologies in which surface modification is employed: ligand addition 
and ligand exchange (68,69). In ligand addition, polymers adsorb to the surface of particles 
physically due to hydrophobic interactions, electrostatic and/or by hydrogen bonding. 
Polymers containing functional groups such as hydroxyl and amine, are adsorbed to the 
SPIONs surfaces readily (70). In ligand exchange, replacing original surface with functional 
groups such as thiol, carboxylic acid, amine, diol, customize surface properties better (71). 
There are other commonly available methods of surface alteration including lipid and micelle, 
biomolecular conjugation, inorganic core-shell formation, use of organic surfactants and 
biofabrication (72). Oligonucleotides, peptides, or enzymes are also important for specific 
cell/tissue targeting and its attachment is done via addition of the specific functional group on 
the coating layer (73). The selection of specific surface modification technique is made 
according to the end use of SPIONs in biomedical field.  
2.4.1 Colloidal Stability  
Three principles control the colloidal stability of SPIONs in aqueous suspension i) 
hydrophobic-hydrophilic interaction, ii) magnetic forces, and iii) Van der Waals forces (4). 
Due to their dominant characteristic of high surface energy and large surface area to volume 
ratio, nano-sized SPIONs tend to aggregate to micro-size clusters (74–76). Van der Waals 
attraction also plays a role to cluster nanoparticles in order to minimize the total surface and/or 
interfacial energy. Microns further agglomerate due to the magnetic dipole–dipole moments 
between them. When an external magnetic field is applied, additional magnetization is added 
which increase their aggregation (74). Using electrostatic stabilization through repulsion of 
charges is typically not sufficient to prevent agglomeration in biological solutions because 
electrolytes such as salts, neutralize the charges (50). Subsequently, these aggregations affects 
the efficacy of SPIONs negatively in drug delivery as larger particles with lower surface area 
limits drug loading and release. It may also result in capillary blockage when injected in the 
body (73). Coating provides steric barrier between the particles, which diminish aggregation.  
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2.4.2 Blood half-life and uptake by the reticulo-endothelial system (RES) 
Blood half-life indicates the circulation time the particles can exist in blood before they are 
removed by RES (77). When nanoparticles are recognized as foreign bodies, elimination by 
phagocytic cells occurs (78,79).  When particles are coated, resistance of non-specific proteins 
adsorption improves, which will in return, lowers the probability of phagocytic cells 
elimination and thus increases blood half-life (76,80,81). In Molday and Mackenzie (82), 
blood circulation was proven to increase when MNPs were coated with dextran in-situ while 
Liu et al. (83) and Woodle et al. (84) showed that coating with a polymer PEGylated 
improved pharmacokinetics and extended blood half-life. Longevity in half-life helps in 
achieving enhanced drug release as well as more time for interaction with target site (6).   
2.4.3 Nano-cytotoxicity of hybrid polymeric-magnetic nanoparticles 
Although SPIONs are considered the most biocompatible compared to other nanoparticles 
such as carbon nanotubes, gold and silica-based nanoparticles bimetallic or magnetic alloys 
such as FePt, metal oxides, such as cobalt and nickel ferrites, its cytotoxicity and genotoxicity 
remain not clearly understood (85,86). Toxicity is evaluated on how nanoparticles interact 
with the body during its functional lifetime, and how the components affect the body during 
biodegradation and liver processing (87). At longer duration times and high concentration, 
bare iron oxide nanoparticles exert some toxic effects while coated SPIONs are relatively 
nontoxic. Gupta et al. found that using PEG-coated SPION, cells remained > 99% viable at a 
concentration of 1 mg/mL. However, using bare SPION, 25–50% loss in fibroblast viability 
was noticed at only 250 microg/mL concentration (88). Similar studies indicated that iron 
oxide nanoparticles with different coating exerts very low to no toxicity in different cell lines 
(89–92). However, it has been shown that coated-SPION can propose some levels of toxicity 
at elevated concentrations (93,94). Therefore, more research is needed in terms of coating 
types and particles exposure timing in-vivo so that their undesirable effects can be avoided.   
2.4.4 Oxidation resistance properties of hybrid polymeric- magnetic 
nanoparticles 
Iron oxides have relatively high oxidation resistance, however, they could be oxidized and 
converted to α-Fe2O3 due to of the presence of exposed Fe2 + in Fe3O4 MNPs (50). α-Fe2O3 
demonstrates no magnetic properties, which affects nanoparticles drug delivery efficiency. 
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Hybrid polymeric-magnetic nanoparticles provide much better stability against corrosion and 
oxidation and allows particles to maintain their single domain structure (95,96). 
2.5 Polymer coating  
Bare magnetic nanoparticles generally, and SPIONs specifically, proposes many challenges in 
vivo such as lack of biodegradability in the physiological environment, chemical instability 
and poor biocompatibility. Coating is an extremely essential factor in achieving successful 
drug nano-vehicles. The fundamental reasons are to attain colloidal stability, longer blood 
circulation, evade cell toxicity and prevent oxidation. Polymer-based surface modification of 
SPIONs is classified into two categories: surface exchange and polymer encapsulation 
(22,97). In surface exchange, polymers replace the original nanoparticles surface similar to 
ligand surface addition except that a polymer substitutes the ligand. In encapsulation, a 
polymer encapsulates the nanoparticle by hydrophobic interactions between the original 
hydrophobic MNPs surface and the hydrophobic section of the polymer chains where the 
hydrophilic section of the polymer faces the media.  
Polymer coating provides a much-enhanced colloidal stability compared to other surface 
modification types due to abundance of chains that provide electrostatic and steric dispersion. 
Aspects that influence polymeric SPIONs performance include, molecular weight or molecule 
length, chemical structure, chemical conformation and the approach in which the coating is 
attached to the MNPs, e.g. covalently bonded or electrostatic attraction (2). The polymer 
molecular weight and configuration contribute strongly to the  
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way the coating is accomplished on the particles surface. Different coating schemes are 
formed depending on the type of polymer such as end-grafted, trains, loops, tails or fully 
coated polymer shells (2,98). Polymer coating is classified into two types: natural and 
synthetic. The most widely studied natural polymer in SPIONs are dextran, chitosan, gelatin, 
and starch; while the synthetic ones include poly (ethylene glycol) (PEG), poly (vinyl 
pyrrolidone) (PVP), poly (vinyl alcohol) (PVA), and poly (lactic-co-glycolic acid) (PLGA) 
(99,100). Figure 2-4 and Figure 2-5 represents different polymers used as primary coating or 
stabilizer for SPIONs sorted by their functional groups, and the polymers chemical structures, 
respectively.  
2.5.1 Natural polymers 
2.5.1.1 Dextran 
Dextran is a biodegradable and biocompatible neutral polysaccharide composed of α-D-1,6-
glucose-linked repeating glucan units, and sometimes has side-chains 1–3 attached to its 
backbone (101). It is considered one of the most extensively studied coating polymer for 
ISPONs and is successfully implemented in vivo applications (69,102).  Its main advantage is 
-OH 
• Polymethylene glycol  
Dextan  
Polyvinyl alcohol  
Pluronic 
-COOH 
Polyacrylic acid  
Carboxymethyl cellulose 
Polyethylene glycol with 
terminal carboxylic group 
-NH2 
Chitosan 
Polyethyleneenimine 
Poly(L-lysine) 
Polyethylene glycol  
Figure 2-4: Polymers used in surface coating of SPIONs, sorted by their functional 
groups. 
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the ability to increase blood circulation time of particles as it stabilizes the colloidal solution 
(82,103). Often Dextran is susceptible to dislocate from SPION cores and thus modification of 
coating layer by functional group addition and covalent bonding is often desirable. Li et al. 
improved stability of coating by addition of carboxymethyl group and cross-linking with 
epichlorohydrin forming cross-linked iron oxide (CLIOs) (82,103) . CLIOs can be prepared 
by physical adsorption followed by dextran cross-linking to provide tighter attachment to the 
core, yet CLIOs without a cross-linking step still showed great stability and biocompatibility 
(73). Enhanced functionality was observed when CLIOs was treated with amine group, which 
then can bond to proteins and peptides (104). Alternatively (104) , covalent conjugation of 
partially oxidized dextran though secondary amine group was performed by Sonvico et al. to 
enhance its stability after a modification to SPIONs surface with aminopropylsilane (105).  
Dextran multivalent nature permits attachment of various molecules at many sites along its 
chain. As a result, further functionalization is often performed by addition of hydroxyl group, 
carboxylate, or aldehyde (73). Sodium periodate can be used to oxidize dextran polymer by 
cleaving the carbon between the two adjacent diols to create an aldehyde. This form of 
dextran is highly reactive and can combine with various amine-containing molecules.  For 
instance, modification of oxidized dextran was done by Cen et. al. (106) in order to generate 
folate and fluorescein isothiocyanate (FITC). Also, TAT-crossed linked dextran coated 
SPIONs (TAT-CLIOs) were synthesized and their effect on cellular localization in human 
lymphocytes were studied (107). TAT-CLIOs was made by epichlorohydrin treatment and 
The TAT peptide is attached via a disulfide linkage and FITC-labeling was performed. Before 
localizing the TAT-CLIOs in the cells and the sytoplasm, cells were treated with anti-dextran 
antibody to ensure that both the CLIOs and the peptide reach the nucleus and not only 
disulfide cross-linked peptide. Immunohistochemical staining showed that CLIOs had indeed 
researched the nucleus and were detectable by MRI as they were highly magnetic. Moreover, 
the study showed the ability dextran coated particles to characterize the nodal stages during 
cancer with an MRI.  
2.5.1.2 Chitosan 
Chitosan is a natural, hydrophilic, biocompatible, bio-degradable, and non-toxic copolymer 
(poly-aminosaccharide): b-(1 → 4)-linked 2-acetamido- 2-deoxy-d-glucopyranose and 2-
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amino-2-deoxy-d-glucopyranose (50,99). Chitosan has repeated hexosaminide residues where 
each unit is made of two hydroxyl groups and an amino group. Chitosan attaches firmly and 
stably to SPIONs surface due to these groups that form complexes with the surface (108). The 
negatively charged nucleic acid in chitosan, on the other hand, can interact with the positively 
charged amine groups for gene delivery therapeutics with MRI (109). This also makes 
chitosan bio-adhesive resulting in increasing retention time at tissue site (110). Chitosan is 
commonly used for coating SPIONs for enhanced quality as contrast agent in MRI (111–113) 
and is known to ease particles movement across cellular barriers and quickly opens the tight 
junctions in epithelial cells (114,115). Synthesis of florescence dye modified magnetic iron 
oxide nanoparticles improves cellular imaging and can serve as both magnetic resonance 
contrast agents for MRI and as an optical probe for intravital fluorescence microscopy. 
Chitosan was attached non-covalently to particles surface after modifying it with covalently 
attached fluorescent dye. Fluorescent modified chitosan allowed for direct imaging and 
localization of particles, which were visible inside the living cells, mostly in late endosomes 
or lysosomes, as well as on cell surfaces via confocal laser scanning microscopy (CLSM) and 
Transmission electron microscopy (TEM). Approximately, 85% of cells contained the FITC-
labeled particles (labeled-cells) 30 min after incubation and within the first two hours. The T2 
relaxivity of the labeled cells in-vitro detected 104 cells with 1.5 TMR Imager and the 
prepared FITC-labeled particles were biocompatible as demonstrated by a cytotoxicity test. 
However, SPIONs still exhibited aggregation that possesses a safety concern in clinical 
application. 
2.5.1.3 Gelatin 
Gelatin is an organic protein derived from collagen. Some of its properties include solubility, 
biocompatibility, biodegradability, and pH-induced surface charge and thus it is used in many 
pharmaceutical and biomedical applications (116,117). Doxorubicin (DXR) creates a drug–
polymer conjugate due to the presence of multifunctional groups in the gelatin chain such as 
COOH and NH2 (118). Gelatin can be fabricated as mirco and nano-spheres depending on 
synthesis technique, and is found to enhance phagocytosis in tumor cells (119). Although 
Gelatin seems to be a suitable candidate as a coating material for SPIONs, yet only few 
studies have been performed on it (120). Intorasoot et al. used Gelatin-coated MNPs for 
bacterial genomic DNA isolation (121). DNA extraction using coated MNPs demonstrated 
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much more efficient results compared to commercially available extraction kit and phenol-
chloroform extraction, where double the amount of DNA was recovered with significantly 
higher yield. Gaihre et al. investigated drug-loading efficiency on two types of gelatin-coated 
iron oxide nanoparticles using DXR as the model drug (116). Two gelatine types (from 
porcine skin vs. bovine skin) were used and drug loading was performed using two different 
methods: 1) adsorption (charge induced of negative coated particles to positive doxorubicin) 
which was done by incubating MNPs and drug in different drug concentrations, pH levels, 
gelatin type, and DXR to coated particles ratios; 2) desolvation/cross-linking method where 
acetone and glutaraldehyde (GTA) where added to the DXR and coated particles mixture. 
Regardless of gelatin type, desolvation/cross-linking technique had higher drug loading 
efficiency. This indicates drug-particles interaction in the loading phenomenon where the 
encapsulation efficiency changes according to surface charge of the gelatin-coated particles. 
Also, loaded particles were pH responsive in drug release with higher release at pH 4 
compared to 7.4.  
 2.5.1.4 Starch 
Starch is a natural long D-glucose chain that has good biodegradability and stability as 
SPIONs coating material. Starch-coated SPIONs with fairly low agglomeration can be 
synthesized by alkaline coprecipitation of iron salt in a starch matrix (122) rat brains for in-
vivo MRI and monitoring. The starch-coated SPIONs showed great biocompatibility and 
feasibility as MR contrast agents in brain scans (123). Also, carboxymethyl starch (CMS-
SPIONs) has been investigated extensively for controlled-release system and analyzed with 
many kinetic studies.  Saboktakin et al. (118)  showed that carboxymethyl starch is a reliable 
coating for SPIONs to achieve stable, spherical and relatively mono-dispersed particles for 
drug delivery of ferrofluid. Core-shell structure was prepared via hydrogen bonding CMS 
alcohol groups with the hydroxylated and protonated SPIONs surface. The study also 
demonstrated that CMS- SPIONs has the capacity to be delivered in cancer tissue, and high 
potential to be used for cancer diagnosis as contrast agents.  
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2.5.2 Synthetic Polymers 
2.5.2.1 Poly (ethylene glycol) (PEG) 
PEG is a linear water-soluble synthetic polyether that is mostly used to enhance solubility of 
hydrophobic drugs (124,125) . One of the main reasons for use of this polymer for preparation 
of many bio-conjugates is its tendency to exclude macromolecules, proteins and other 
particulates from its surrounding. It shows no adverse effect on enzyme activities or protein 
conformation in aqueous solution when used as coating material (126) and causes no immune 
interactions while increasing circulation time when MNPs are coated with PEG (99,127–129). 
PEG enhances steric stabilization in vivo, thus prolongs blood circulation. It is highly 
internalized by cells with no toxicity due to its high solubility and fluid phase (130,131). PEG 
molecule has only one hydroxyl group at the end of its chain, which results in reduced further 
functionalization of coated SPIONs-PEG (73). Nevertheless, the coating of PEG acts as a 
good spacer, which allow for various biomolecules attachments (132,133).  Novel SPIONs 
coated with polyethylene glycolylated bilayer was reported for synthesizing small (60-100nm) 
and ultra-small (20-35 nm) particles with narrow size distribution (134).  
A simple method for preparing PEG-IONPs by hydrolysis was described by Kumagai et al. 
(135). Hydrolysis using FeCl3·6H2O in water with addition of PEG and poly (aspartic acid) 
block copolymer. These particles expressed great stability and solubility in aqueous media and 
in physiological saline. Recently, PEG coated IONPs are mostly loaded with cancer drugs for 
in-vivo applications. Hałupka-Bryl et al. (136), synthesized PEG coated IONs loaded with 
DOX via coprecipitation method and presented their in-vivo use possibility though analysis of 
their physical and magnetic properties. Interestingly, Nazli et al. showed that PEG coated 
SPIONs can be taken by cancer cells 11 times more efficiently than bare nanoparticles. The 
study reveals the use of IONPs coated with integrin-targeted and matrix-metalloproteinase 
(MMP) which is a sensitive PEG hydrogel. The PEG hydrogel coating with functionality was 
designed for active targeting and intra-cellular of DOX.  
2.5.2.2 Poly (vinyl pyrrolidone) (PVP)  
Poly (vinyl pyrrolidone) (PVP), made from the monomer N-vinylpyrrolidone, is an is a non-
ionic, soluble, chemically inert synthetic linear polymer (137). PVP, or sometimes referred to 
as povidone or polyvidone, is synthesized in a range of molecular weights, from 
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approximately 1 to 103 kg/mol by radical polymerization of vinylpyrrolidone, and are 
classified based on their K-value. PVP is used widely in pharmaceutical industry as a binder 
and in many cosmetics and as food additive. PVP coated SPIONs synthesized with narrow 
size distribution of 10-20 nm was shown to enhance the blood circulation time and increased 
in colloidal solution stabilization in drug delivery. It was also investigated for its effect as 
contest agent, where IONPs-PVP was synthesized by thermal decomposition to study its 
efficiency in MRI (138) . The produced particles of 8–10 nm had macrophage uptake similar 
to Fexidex with magnetization of 110 emu/g Fe, compared to that of 70 emu/g Fe for Feridex. 
Huang et al. (139) studied the effect of particle size on PVP-coated iron oxide nanoparticles in 
the range of 30-120 nm on cellular uptake and Liver MRI. It was found that contrast 
enhancement and RES sequestration of PVP-IONs was strongly size dependent with particles 
having 37nm core and 100nm hydrodynamic size demonstrated the best enhancement. 
Interestingly, Lu et al. (140) investigated the dispersibility of PVP-Fe3O4 nanocrystaled 
synthesized via “one-pot” method. Ten types of aqueous solutions and organic solvents were 
used with varying pH values. It was shown that PVP-Fe3O4 is super-dispersing in all mediums 
forming stable colloidal mixture.  
2.5.2.3 Poly (vinyl alcohol) (PVA) 
PVA is a very attractive hydrophilic synthetic polymer that is extensively used in many 
industries including pharmaceutical industry and in biomedical research. PVA exhibits 
important properties such as biocompatibility, excellent film/gel forming, and adhesive 
properties (141). PVA coated magnetic nanoparticles synthesized with narrow size 
distribution of 10–50 nm was studied for In-vivo imaging and drug delivery applications 
(142,143). PVA impressively assisted in preventing coagulation by steric hindrance 
mechanism, providing colloidal stabilization, and consequently increasing mono-dispersed 
particles. Applying proper amount of PVA is vital in achieving the desired properties. It is 
reported that high amount of PVA polymer to iron mass ratio greater than 3, results in 
magnetic bead formation which reduces SPIONs crystallinity and affects cytotoxicity 
profile negatively (142,144). Mahmoudi et al. showed that the critical mass ratio was 
approximately 3, where the highest levels of magnetic saturation and the permeability of 
SPIONs was detected (90). Lower ratio values had no significant outcome on magnetic 
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saturation while higher than 3 ratios resulted in the formation of magnetic beads. PVA-coated 
SPIONs was investigated for cytotoxicity evaluation on mice fibroblast cells (L929), showed 
that particles with ratio r=3 coating had good biocompatibility (95% cell viability). Moreover, 
Petri-Fink et al. (145) studied the effect of PVA and the thiol, carboxylate, and amino-
functionalized derivatives of PVA coated SPIONs on Melanoma cancer cells. The PVA-
SPIONs interacted with the tumor cells and was shown to be dependent on the chemical 
structure of polymeric coating. 
2.5.2.4 Poly (lactic-co-glycolic acid) (PLGA) 
PLGA is used in a large crowd of FDA approved products for its advantages in biomedical 
engineering generally and in drug delivery specifically. It is a biocompatible, hydrophilic, 
biodegradable and low toxic copolymer. PLGA is made of two monomer, the cyclic dimers 
(1,4-dioxane-2,5-diones) of glycolic acid and lactic acid. When degraded, these two 
byproducts are carbon sources for Krebs cycle or the tricarboxylic acid cycle, thus are 
eliminated safely from the body in the form of water and carbon dioxide (146). PLGA 
crystallinity varies strongly from fully amorphous to fully crystalline depending on LA/GA 
monomer ratio. Subsequently, PLGA affords a controlled drug release profile when coated on 
SPIONs as degree of degradation can be adjusted though its crystallinity (147). Iron oxide 
coated the PLGA nanoparticles are synthesized by emulsification–diffusion procedure in 
most reported literature (148–150).   
PLGA is the most used polymer coating to improve the labeling efficiency of SPIONs to 
cancer cells (151). Hajikarimi et al. (151) investigated the uptake and cytotoxic effects of 
PLGA-coated-IONs as a drug carrier of 5-fluorouracil (5-FU) on prostate cancer cells 
monolayer culture. Cells where treated with free 5-FU as a control and 5- FU loaded 
nanoparticles with combination of X-ray radiation. It was found that these carriers were 
excellent in penetrating into the cell with effective drug delivery, as reduction in colony 
number was significantly higher in 5-FU-loaded IONs. Also, PLGA encapsulated Oleic acid 
coated magnetite was synthesized for the purpose of studying its toxicity effect on MCF-7 
cells after loading them with DOX, an anti-cancer drug. Cell death was drastically higher in 
DOX loaded nanoparticles compared to drug free ones, indicating that these DOX-PLGA-
MNP are appropriate for targeted drug delivery purposes. Cheng et al. (152) prepared various 
34 
 
sizes with narrow distribution of iron oxide PLGA-coated NPs via nanoprecipitation method. 
These particles were fluorescein isothiocyanate encapsulated and conjugated with quantum 
dots. They showed a controlled release pattern and yielded a high efficiency in relaxivities, 
demonstrating their effectiveness as contrast agents. Also, Hwang et al. (153) examined their 
detection as contrast agents in MRI and optical imaging systems after associating them with 
transplanted pancreatic islets in-vivo. PGAL-IONs containing cyanide dye were successful in 
labeling the transplanted islets in both imaging systems, where docyanine green fluorescence 
appeared after 2 and 4 days of transplantation in optical imaging and scans were monitored in-
vivo MR after 4 weeks. Figure 4 shows the chemical structures of main natural and synthetic 
polymers used in SPIONs coating. 
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2.6 MNPs in drug delivery and therapeutic platforms  
2.6.1 Chemotherapeutics agents  
Cancer is one of the major medical research challenges and most difficult to treat because of 
difficulty in timely diagnoses and limited treatment options. The treatment options available 
can be very devastating to human body (surgery, chemotherapy and radiation) and have 
enormous adverse side effects. There has been extensive research done to find innovative 
ways to solve cancer treatment limitations. Most chemotherapy remedies rely on cytotoxic and 
cytostatic effects with no specific cell-targeting capabilities (54). Fortunately, MNPs have the 
capability to be engineered for target-specific cell internalization carrying chemotherapeutic 
payload and the subsequent drug release to cell cytoplasm for desired actions to be carried out.  
Studied mechanisms on magnetic nanoparticles uptake by the cells include internalization by 
caveolae structures (154) and receptor-mediator endocytosis (155). As previously stated; 
particles shape, size, surface properties affect cellular uptake efficiency drastically. Also, 
permeation enhancers can be attached to MNPs to ease its delivery to cytoplasm (156).  Koch 
et al. (157) showed the effective use of tat-CLIO nanoparticle in cell tracking in drug delivery 
applications. They demonstrated rapid internalization, 100% labeling cells in less than an 
hour, and slow excretion of nanoparticles, in a period longer than 144 h from the adopted 
cytoplasm. Upon MNPs merging into targeted cells, the challenge of drug release arises.  
Nanoparticles must be able to deliver desired chemotherapeutic to subcellular organelles such 
as the nucleolus and mitochondria before being ejected from the system by lysosomes. 
Strategies for release includes enzymatic cleavage, physiological conditions alteration such as 
 
Poly (vinyl alcohol) (PVA) 
 
Poly (lactic-co-glycolic acid) (PLGA) 
Figure 2-5: chemical structures of the main natural and synthetic polymers used in 
SPIONs coating 
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change in pH, temperature and osmolality, or “proton sponge” effect which is the 
incorporation of cationic polymers which produce osmotic swelling (73,158). There are many 
cancer drug formulations associated with MNPs such as doxorubicin, paclitaxel and 
methotrexate (MTX), epirubicin (206,209,221). Incorporating these drugs into nanoparticles 
have been explored extensively to be loaded and protected until reaching cancer cells, where 
cytotoxic drug molecules will deliver its therapeutic effect. Most hydrophobic drugs are 
loaded via physical adsorption, in which encapsulation are done within MNPs coating 
restricting non-specific cell interface (54). This technique can be applied to drugs causing 
severe damage to non-targeted cells. On the other hand, other cancer drugs that hold affinity to 
aimed cells through presence of chemically active functional group, MTX for example; it is 
directly attached to surface of MNPs through mild chemistry or strategic crosslinking. MTX 
loaded into polymeric IONPs were studied in many trials. Amine terminated PEGylated saline 
was used to modify IONPs, and MTX was consequently loaded via EDC/MHS mediated 
coupling as reported by Kohlar et al. (159). The particles were examined in glioma cell uptake 
in-vitro. Proceeding to the cells internalization, MTX was detached due to presence of 
proteases and low pH in the lysosome. The unique superior magnetic property makes MNPs 
responsive, aggregately and easily controlled once an external magnetic field is applied. This 
method or so called Magnetic drug targeting (MDT) is advantageous for transporting cancer 
drug-loaded MNPs to the area of interest at the desired rate (160,161). Many studies have 
been performed to investigate the concentration of MNPs upon addition of external field in-
vivo. Lubbe et al. (162) conducted a study on rats where epirubicin loaded 100 nm IONPs 
coated with polymeric anhydroglucose partially functionalized, were injected into their 
femoral vein (estimated to 0.5% of rat blood volume). Upon magnetic field influence of 0.2 T 
for 5, 10 and 30 minutes, irreversible thrombus was observed after 10 minutes with display of 
microcirculation in the capillary bed. This demonstrates the ability of loaded SPIONs for use 
in mechanical tumor embolization. Similar experiments were conducted with same 
observations (163). In a different study also prepared by Lubbe et al., full tumor regression 
was achieved of starch coated SPIONs loaded with epirubicin for severely metastasizing 
adenocarcinomas and hypernephroma implanted in mice (164). Encouragingly, human clinical 
trials have also been reported. Using the same loaded anhydroglucose-SPIONs from Lubbe et 
al., seven breast cancer patients in the fourth stage were injected with the same 
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anhydroglucose-SPIONs. Vain injection was positioned contralateral to the tumor and the 
magnetic field placed on the tumor was applied for 45-105 minutes, and successful regression 
and direction to tumor site was reported. No apparent clinical symptoms were observed except 
for skin discoloration in both animal and human trials which appeared 7-14 days latter 
(160,162). Doxorubicin release on-demand in-vivo was assessed by Lee et al. (165).  
Significant tumor volume suppression was shown through injection of magneto-thermally 
responsive nanoparticle system after 15 days of treatment. Comparably, trials with groups 
given double injections of Dox_NPs exhibited continued and improved tumor growth 
inhibition. Interestingly, however, studies have shown that application of external stimuli in 
drug release, magnetic field in this case, results in a drug release reduction because of 
aggregation of the magnetic nano-hybrid particles (166,167).  
Combination of more than one cancer therapeutic agents loaded nanoparticles to multiple 
targets has also been examined. A novel approach of sequential release of two drugs endocrine 
and chemotherapy, tamoxifen and diosgenin respectively, in advanced breast cancer cells was 
recently evaluated by Kumar et al. (34).  A multi-layered polyvinyl alcohol hollow manganese 
ferrite nanocarriers were designed and synthesized with very unique features: having 
sensitivity towards tumor acidic milieu, compact, high encapsulation efficiency and mono-
dispersed. Mediating drug(s)-induced cell apoptosis in-vitro and in-vivo, it was shown that 
tumor suppressor protein P53 was stimulated while antiapoptotic Bcl2 protein level was 
decreased as confirmed by protein profiling, immunohistochemical, and mitochondrial 
membrane potential investigations. This result shows the success of multi-drug nanoparticle 
delivery system and may provide promising treatment approach for advanced cancer. Fang et 
al. (168) highlights the effectiveness of using dual drug-delivery using nanocapsules. 100-150 
nm core-shell nanostructures made of PVA, polyvinyl alcohol (PVA), polyacrylic acid (PAA) 
and iron oxide and loaded with doxorubicin and curcumin were designed. High accumulation 
at brain tumor cells in bearing mice was observed after intravenous administration and 
magnetic field application at targeted site. Impressively, cancer growth suppressing in vivo 
was more efficient than the delivery of either drug alone. 
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2.6.2 Hyperthermia treatment 
As explained earlier, the advantage of superparamagnetic in contrast with ferromagnets 
nanoparticles is the absence of magnetic remanence after application of magnetic field, in 
which problems with particles aggregation is prevented (169) . However, the magnetic 
dynamics of remanence recovery is relatively slow. Applying a high frequency alternating 
magnetic field can better control it resulting in release of energy in a form of heat, termed as 
magnetic hyperthermia. Extensively studied lately, this effect provides a promising cancer 
therapy through raising cells temperature abnormally (41–45 °C) (170). The damage of 
normal cells in this temperature range is reversible whereas it is irreversible to cancer cells 
(171). The detection of the effect of heat generation on cancer cells was first studied in the 
19th century (172), where administration of living bacteria to cancer patients was carried out 
causing an infection associated with a fever. It was observed that fractional tumor regression 
has occurred, but also neighboring healthy tissue was effected significantly. Enormous studies 
have been done in attempt to find alternative mechanism to control heat generation 
(104,173,174). Magnetic fluid hyperthermia (MFH) is a possible solution to that problem, 
where it is based on colloidal suspension MNPs injection at tumor cells through passive or 
active targeting, then MNPs are used as mediators of hyperthermia for localized treatment 
(175).  
MFH opens many doors to new cancer therapy that is non-toxic, non-invasive with relatively 
no damage to normal cells with high efficiency of killing cancer cells by heat diffusion. 
Additionally, MNPs used in Hyperthermia can be engineered to target tumor sites via specific 
agents or antibodies and can also serve for diagnostic purposes in MRI before heating to 
detect particles distribution (104). Recent trials in mice models demonstrated the success of 
MFH in many types of cancers such as brain cancer (176) and pancreatic tumors (177).  
Furthermore, combination of MFH and targeting ligands maximized tumor targeting and 
improved treatment efficacy. Ito et al. (178) used Anti-HER2 antibody functionalized 
immunoliposomes containing magnetite nanoparticles with hyperthermia therapy at 42.5°C. 
This system showed great potential in treating HER2-overexpressing cancer. In another study 
by Tsiapa et al. (179), peptide RGD derivate (cRGDfK-Orn3-CGG) coated MNPs was used 
accompanying heat therapy of approximately 39°C. High targeting ability in U87MG 
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glioblastoma tumor-bearing mice was observed while accumulation of MNPs in neighboring 
organs was negligible. Tumor volume reduction was confirmed by dissection of tumor 
following hyperthermia treatment. 
2.6.3 Radio-therapeutic agent  
Radionuclides, mainly β-emitters, have localized decay in target cells, which promotes DNA 
to damage free radicals that result in apoptosis, hence, they can function as cancer therapeutic 
agents. Recently, SPIONs and some other nanocarriers were recognized as radionuclides 
(180). Similar to chemotherapeutics, there are no clear guidelines on targeting strategy in 
place yet for radio-therapeutics to direct them away from healthy cells towards cancer cells. 
Unlike chemotherapeutics, however, engineering SPIONs in radiotherapy is uniquely 
challenging since radionuclides are continuously decaying making it very difficult to avoid 
healthy cells. Thus, even after cell uptake, SPION-radionuclide complex has to be kept intact 
throughout radiation decay to avoid interaction with non-targeting cells. The most used 
radioactive isotope to develop radionuclide-SPIONs is 188Re with half-life of 17 hours, which 
showed ability to induce cell death in specific targeted liver cells in vivo (181–183).  
There are several studies present that address the combination of radiation and hyperthermia 
(184,185). The higher the formation of free radicals to DNA damage ratio, the better efficacy 
of radiation therapy. When Hyperthermia is added, it increases local oxygen levels due to 
increase in blood supply to tumor cells. This causes more formation of free radicals resulting 
in enhancing radiation therapy. In one clinical study (186), 59 patients with recurring 
glioblastoma were injected with IONPs followed by 30 of heating at 43 °C. A radiation dose 
of 30 Gy was then given immediately after or before hyperthermia therapy. The combination 
of therapy raised the median overall survival rate from 14.6 to 23.2 months since the primary 
cancer diagnosis and 7.2 month from recurrence date. The increase in survival is believed to 
be due to the duel thermo-radiation therapy.  
2.6.4 Gene Therapy and Magnetofection (MF)  
Gene Therapy is the use of exogenous DNA to correct genetic defects or to produce 
proteins/peptides that enhance the immune system (73). Antisense RNA can also be used in 
gene therapy for expression silencing of defective genes (54). This major advancement in 
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modern medicine can be applied in wide range of applications including but not limited to: 
genetic disorders, cardiovascular disease, cancers or neuro-degenerated disease. Development 
of effective gene delivery system that distribute plasmid DNA and insert it in specific DNA 
sites is the curial aspect determining gene therapy success (187). Regardless of the substantial 
research conducted, no ideal effects of gene therapy are present due to many challenges. 
Transfection efficiency is greatly lacking in terms of targeting desired sites with no toxic or 
hostile side effects due to lack of specificity, genes short life time in vivo and poor diffusion 
across cell membrane (188,189). Using MNPs as carriers for antisense oligodeoxynucleotides 
(ODNs), termed as Magnetofection, may minimize many of these problems. MNPs and gene 
therapeutics have been integrated as a gene vectors to protect the nucleic acids from 
enzymatic degradation and enable endosomal release after cellular internalization (190). There 
are many advantages of MNPs-based transfection including low vector dose to achieve high 
transfection yield, potential use as viral and non-viral vectors, ability to attain high efficiency 
and short incubation time transfection/transduction, ability to deliver genes to non-permissive 
cells and the possibility of precise targeting in-vivo (73,191). Particularly, polymeric MNPs 
have an advantage since polymers, such as PEI and chitosan, can enrich endosomal release via 
acidification induction of endosomal vesicles (192).  The efficiency of this system has been 
proven in vitro and still under studies for in vivo applications. Gene vector attached to PEI 
coated SPIONs, named tranMAGPEI was tested in vitro were a strong magnet was placed 
beneath the cell monolayer. After 10 minutes of incubation, peak transfection levels were 
observed, in comparison to 2-3 hours of incubation required to other vectors such as cationic 
lipids. High concentration of MNPs vectors at the surface results in noticeably improved dose-
response profile (193). Pan et al. (194) develop a dendrimer-modified MNPs for delivering 
antisense survivin oligodeoxynucleotide to liver and breast cancer cells.  Results indicated that 
the particles were successfully delivered within 15 minutes among cell growth inhibition in 
time and dose dependent manner. Other magnetofection studies on liver cancer cells showed 
also similar results (195,196).  
 2.6.5 Peptides/antibodies therapeutics 
As MNPs facilitate as drug molecules carrier, so as it can be carrier of peptides or anti-bodies. 
These biotherapeutics serve as a great potential for therapeutic agents due to their ability to 
manipulate cell-specific desired mechanism. They control their remedial effects through 
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stimulation or inhibition of particular cell activity involving immune system stimulation, 
activation of apoptosis, or function blocking such as angiogenesis, cell adhesion prevention, 
interfering with protease/ kinase action and others (197) . Therefore, engineered MNPs must 
have appropriate size, reported as 25–50 nm hydrodynamic size (198), and coating, such as 
PEI which enables internalization for example, in order fit with most biological pathways. 
RGD (Arg-Gly-Asp) is a frequently used peptide with SPIONs. It contains the receptor 
integrin αvβ3 in which tumor blood vessels and some melanoma cells has over-expressed 
amount of it (199).  Recently, chlorotoxin (CTX) peptide is examined due to its high affinity 
to many cancer types. In addition to being targeting agent, it suppresses tumor growth through 
inhibition of cell invasion mechanism. Veiseh et al. (200), studied the potency of CTX peptide 
on SPIONs conjugated with an amine-functionalized poly (ethylene glycol) silane. CTX has 
high attraction to lipid raft-anchored that includes both membrane-bound matrix 
metalloproteinase 2(MMP-2) and chloride ion channels, which are important elements in 
glioma cancer survival and cell invasion. Through cells receptor-mediator endocytosis, MNPs 
has greatly enhanced cellular uptake, thus prohibiting targeted cells ability to affect 
neighboring healthy tissue. SPION-CTX had an improved internalization and invasion 
inhibition rate up to 98%, compared to free CTX particles of 45% only. Moreover, antibodies 
had also shown great effect with SPIONs as targeting agents. Their efficiency is proven since 
most of the commercially available magnetic nanoparticle systems are labeled with antibodies 
against bacteria, epitopes of cells or other antigens (201). One example is Herceptin, marketed 
as Trastuzumab, is incorporated with SPIONs targeting HER2/neu receptor, which is 
responsible for cell proliferation and serves in cell growth. Herceptin™- magnetite 
nanoparticle were proven to anti-proliferate breast cancer cells (202,203). Furthermore, other 
studies have collaborated anti-HER2 antibody therapy with hyperthermia using IONPs had a 
much higher therapy efficiency with increasing cytotoxic effect (202,204).  
2.6.6 Hybrid magnetic nanoparticles for mitochondrial targeted anticancer 
drug delivery 
The mitochondrion plays an important role in controlling the translocation of pro-apoptotic 
proteins to the cytosol. In other words, mitochondria have a direct impact on the non-apoptotic 
cell death (205). There is increasing evidence about the correlation between mitochondrial 
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dysfunction and a variety of neurodegenerative diseases, diabetes and cancer. Therefore, 
mitochondrial targeted compounds represent a promising approach in cancer treatment.  
One of the major differences between the normal and malignant cells is the presence of 
negative potential (20-60 mV) on the inner mitochondrial membrane. However, difficulties 
remain in mitochondrial-targeted therapy due to the possible degradation of drugs before 
getting access to its target points. So far, there are only few publications on the successful 
mitochondrial targeted drug delivery systems (206,207).  Surface modified chitosan has drawn 
great interests for the development of mitochondrial targeted drug delivery systems. Chen et 
al. (208) have investigated two chitosan derivatives (N-glycyrrhetinic acid-polyethylene 
glycol (PEG)-chitosan (NGPC) and N-quaternary ammonium-chitosan) as possible drug 
carriers for targeting the mitochondrial inner membrane. The presence of quaternary amine 
group in N-quaternary ammonium chitosan and PEG in the NGPC helped in pH cleavage of 
the surface modified chitosan. Smart Fe3O4-quaternary ammonium chitosan or Fe3O4-NGPC 
hybrid nanoparticles have shown a good promise in targeting cancer cells because of the 
endosomal escape and mitochondrial targeting. Typically, magnetic nanoparticles approach 
the tumor site by the effect of the tumor targeting N-glycyrrhetinic acid. Following the step of 
endocytosis, the pH cleavable functional group creates a strong positive potential on the 
surface of magnetic nanoparticles; which facilitates the proton influx to endolysosomes. The 
increased proton influx leads to endolysosomal bursting, thus creates favorable conditions for 
magnetic nanoparticles to escape back to the cytoplasm. The positive charge on the surface of 
magnetic nanoparticles facilitates their attachment into the inner mitochondrial membrane and 
results in an efficient drug targeting.  
2.7 Routes of administration  
As stated earlier, the fate of MNPs and its bio-distribution are dependent on countless factors 
such as size, protein adsorption, surface characteristics, stability, molecular weight, drug 
loading and release kinetics. Nevertheless, their destiny, and possible toxicity effect, is 
strongly reliant on the dose and route of administration. This section will discuss briefly the 
most commonly used ways of administrations for MNPs.  
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2.7.1 Parenteral administration  
Generally for parenteral applications, the nanoparticles must meet three conditions: i) non-
toxic, ii) suitable size to be delivered to target site and iii) non-immunogenic. Once MNPs 
reache blood stream, filtrations starts via RES system response. Large particles will be cleared 
out by cells capable of phagocytosis (dendritic or macrophages cells), and small particles are 
removed by cells capable of endocytosis (B and T lymphocytes), while biodegradable MNPs 
are taken by any type of cells via pinocytosis. Particles smaller than 4 microns are cleared out 
mostly in liver (60 -90%) and spleen (3-10%). Particles 200nm and larger are filtered by 
spleen, whereas particles 100nm and smaller are phagocytised by liver cell (209). Parenteral 
administration can be performed by intravenous, subcutaneous or intra-arterial (Carotid artery) 
administration. Recent study demonstrated that magnetic targeting for tumor via intravenous 
administration is effective by passive and active targeting (210). Intra-arterial have the 
advantage in that the vasculature of tissue receives higher plasma concentration, especially 
under low blood flow rate condition and is proven through mathematical analysis (211,212). 
Intra-arterial administration was tested for chemotherapy agent delivery for brain tumor and it 
validated higher tumor exposure for fast eliminating drugs (213,214). Subcutaneous 
administration, on the other hand, is a local injection of colloidal carriers of 60 nm or smaller 
(215). They infiltrate around the injection site and then are absorbed gradually by lymphatic 
capillary system (216). It is used as a tool for lymphatic tumors but not as commonly studied 
because it is not a suitable method of administration for metastatic tumors.  
2.7.2 Oral administration  
Oral delivery demonstrates one of the easiest routes for patients for its painless, non-invasive 
and ability of self-administration (217). However, the main problem of this route is that 
nanocarriers surface modification, peptides and proteins, degrade in the gastrointestinal acid, 
which leads to low or no absorption and burst release of drug initially (218). Thus, MNPs 
must be engineered in a way to have mucoadhesive features. NPs coated with chitosan have 
shown to increase the retention time in the gastrointestinal tract (GIT) and improve therapeutic 
efficiency (219). Typically, the smaller the particles size the higher the mucosal interaction 
and the more the half-life and drug bioavailability. Feng et al. (220) explained the fate of 
chemotherapeutical NPs in oral administration. Study states that particles smaller than 5 µm 
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are removed by lymphatic drainage, particles 500-50 nm are capable of crossing the epithelial 
cells and particles 50 nm or less can pass through intestinal epithelial cells.  
2.7.3 Inhalatory administration 
Airway is a great route in providing large absorption area for treatment of many pulmonary 
diseases (asthma) and non- pulmonary diseases (i.e. infectious diseases) with low systematic 
delivery and contrary effects (221). Various drug categories such as proteins, hormones and 
peptides display an enhanced therapeutic efficiency when are pulmonary administered (222). 
It provides the ability to maximize deposition level and the dose administered and offers a 
much more compliance to patients since it is non-invasiveness drug delivery and can allocate 
both local and systemic therapy (223). Pharmaceutical Products for inhalation purposes have 
specific features that must be met in order to penetrate deeply in the lungs (224). This includes 
specific mean aerodynamic diameter, low size distribution, high drug release efficiency, 
permeability, effective adhesion to lining mucosa and high permeability (225). Polymeric 
micro-and nanoparticles delivered though pulmonary track showed to improve therapeutic 
index of drug though modification of its bioavailability, in which both drug absorption rate 
and drug metabolism reduction is achieved (223).  
 
Table 2-2: the main clinically approved SPIONs in drug delivery. Data 
collected from (15,226–230] 
45 
 
 
 
 
 
 
 
 2.8 Clinically approved SPIONs 
Most of MNPs in trials and approved nanoparticles are focused towards cancer nano-therapy 
due to physical and chemical magnetic property which allow use as therapeutic vehicle and 
contrast agents (226). Current work toward clinically approved magnetic nanotherputices aims 
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to develop personalized medicine with real time monitoring of biological response to the 
given therapy (226). Most clinical trials performed on MNPs and/or approved ones are SPION 
are based on inorganic iron oxide cores coated with hydrophilic polymers (15). Some serve as 
bowel contrast agent such as Gastromark and Lumiren; others are for liver and spleen imaging 
such as Endorem and Feridex; and Lymph node metastases detection such as Combidex 
(15,226).  To date, 5 SPIONs based contrast agents are approved clinically (Table 2-2). 
Ferumoxytol is the most recent FDA approved for the treatment of iron deficiency anemia 
(IDA), used as iron replacement for adults with chronic kidney disease (CKD) (15). Currently, 
14 out of 23 cases of SPION FDA approved clinical underway trials uses Ferumoxytol, ten of 
these cases uses Ferumoxytol as MRI contrast agent in early stage tumor, lymph node cancer 
metastasis, multiple sclerosis and for cardiovascular diseases applications; while the other four 
are in phase IV for DIA (231). Ferumoxytol is more effective than conventional MRI, which 
doesn’t provide detail information on the tumor margin of aggressive tumors such as 
pancreatic carcinoma. Patients having Ferumoxytol-enhanced scans can offer better primary 
tumor allocation and assist in achieving tumor-free margin during surgery of pancreatic 
carcinomas (232). Ferumoxides, on the other hand, is used for detection of liver lesions and 
had been communalized since approval. However, it was withdrawn from the market by the 
manufacturer company, AMAG Pharma , due to its limited use by radiologists in 2008, yet, its 
application in active cell MRI tracking is still documented (233). Presently, four FDA 
approved trials with Endorem for tracking inflammation cell or monocyte, and a phase II stage 
study using Feridex for tracking bone marrow derived stromal cells (MSC) in severe cases in 
adults (234). Ferucarbotran is an organ-specific contrast agent for small liver lesions and was 
shown to be very safe in clinical trials (15). Due to the trials successes, further investigations 
on Ferucarbotran derivative, Supravist, are conducted by Bayer Schering and are now at phase 
III study to be used as a positive improving blood pool agent (226). Furthermore, Ferumoxsil 
and Ferristene are oral admiration SPIONs imaging agents coated with silicone and 
polystyrene, respectively.  They are applied in gastrointestinal to differentiate between bowel 
loops and other abdominal organs as it darkens the bowel when ingested (226).  Nevertheless, 
these two agents were eliminated from the market as they suffered from negative profit 
although they are safe and effective. In addition, Ferumoxtran-10/Combidex® and 
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ClariscanTM are under clinical trials with promising results especially Ferumoxtran-10. It is 
approved in some European countries but still at testing phase for detection of brain and 
pancreatic tumors and metastatic disease in lymph nodes in the USA (227). Other products 
that are present in the market are CellSearch® and NanoDXTM™, both of which are FDA 
approved used for magnetic detection of cells in vitro (226). CellSearch® (Veridex 
LLC/Johson &Johson) is a diagnostic device that uses SPION-bound antibodies to capture and 
then quantify the circulating colorectal, breast or prostate cancer cells in blood samples (235). 
On the other hand, it is worth to note that polymer micelle based SPION are also greatly 
expanding in research towards clinical approval. They are composed of four components: i) 
hydrophilic shell surface, ii) hydrophobic SPION crystallites with hydrophobic polymer 
segments, iii) therapeutic drug or gene agents, and iv) targeting ligands on shell. However, 
micelles are beyond the scope of this review.  
2.9 Industrial applications and scale up 
Since the extent of SPIONs applications in nanomedicien is increasing and already existent in 
clinical use, larger amounts and higher production rate at reasonable prices is indispensable. 
Scale up does not only requires production process to be safe, cost effective, and simple, but 
also requires the nanoparticles to be dispersible in water, biocompatible and holds the desired 
physiochemical properties. Attempts for scale up synthesis of SPIONs were reported. 
Kolen’ko et al. worked on SPIONs scale up via co-precipitation method using iron precursors 
of FeCl3·4H2O and FeCl3·6H2O (236). Although yield was considered on the low side 
(approximately 68%) with poor mono-dispersity of nanoparticles, these particles did have 
good particle size (20 nm), exhibited superparamagnetic behavior with high magnetization (up 
to 84 emu/g), and its performance in magnetic hyperthermia was excellent. Also, Scale-up 
synthesis of MNPs using thermal decomposition method of iron (III) acetylacetonate in 1-
octadecene was studied by Ibarra-Sánchez et al. (237). The produced nanoparticles were 
shown to be sensitive to stirring rate, reaction temperature and stirring time. Although these 
parameters could be optimized to obtain desired nanoparticles size and size distribution, the 
produced nanoparticles are hydrophobic and need ligand exchange procedure prior to being 
applicable in-vivo. Gonzalez-Moragas et al. (238) produced SPIONs with well-established 
magnetic properties and colloidal stability by microwave-assisted reaction. With a yield of 
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around 80%, 3 grams of SPIONs were approximately gathered compared to the average 22 mg 
per batch in normal lab-scale procedure. Interestingly, From a 30 L of bacterial fermentation 
process, over 1 kg of good mono-dispersited Zn-substituted magnetite was recovered by moon 
et al. (239)  Microbial process possesses high yield, reproducibility at relatively low cost and 
energy, However, the production rate is much slower compared to most of synthesis methods 
(up to several weeks) which maybe inconvenient at the industrial level. Overall, steps toward 
the scale-up of MNPs synthesis using different production procedures is improved. However, 
all have limitations and future investigation in that field is desperately needed.  
2.10 Mathematical models of drug release from hybrid polymeric-
magnetic nanoparticles 
A variety of techniques are used in the drug loading into SPIONs: i) the drug molecules can be 
loaded onto the polymeric matrix surrounding SPIONs, ii) encapsulated into a core-shell 
stimuli responsive hydrogel, iii) Covalently bonded to an activated surface SPIONs and iv) 
trapped in magneto-liposomes. Figure 2-6 graphically illustrates the different alternatives for 
drug encapsulation into SPOINs.  
The main objective of drug release control in nanocarriers is to preserve drug concentration in 
blood and/or target site at the effective level. Release kinetics aims to maintain the release 
profile at the therapeutic window via achieving the balance between the minimum effective 
concentration (MEC) and the minimum toxic concentration (MTC). At initial administration 
of a single large dose, drug level is elevated above the MTC resulting in toxic side effects then 
it rapidly drops below the MEC. This gives very minimal timing to have the dosing at the 
effective operational levels. Within a certain interval, multiple dosing can decrease these 
fluctuations, but it proposes many incompliance concerns to the patient (240). Thus, it is of 
great importance to achieve optimal design of new system by developing carriers having 
sustained release profiles with low dosing frequency. 
49 
 
 
 Mathematical modeling aids in predicting the temporal release of molecules through 
understanding the release mechanisms and ensuring proper system design. Drug release 
mechanisms can be classified into four categories: i) diffusion-controlled, ii) chemically 
controlled, iii) solvent-controlled, and iv) stimuli-controlled release (240,241). Most 
frequently, models are built according to the diffusion mechanism (241), which is 
demonstrated as a reservoir system in which the drug is dispersed in a core surrounded by 
polymeric membrane (225). When no membrane is present, a matrix type system is followed 
where diffusion mechanism can also apply with high initial release followed by slower rate 
(243). Fick's law of diffusion describes the drug transport and can be used as the bases for 
diffusion models (Eq. 2-2 and 2-3) (244).  
Figure 2-6: Graphical illustration of the various techniques of drug encapsulation 
in magnetic nanoparticles for targeted magnetic delivery: a) loaded into polymeric 
matrix surrounding SPIONs, b) trapped in magneto-liposomes, c) Encapsulated 
into a core-shell stimuli responsive hydrogel, and d) Covalently bonded to an 
activated surface SPIONs.  
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!"#!" =   𝐷!"   !!!"  !!!                                                                                                      (Eq. 2-3) 
Where, ci is the concentration, ji is the mass flux of species i. Dip represent the diffusion 
coefficient of species i in the polymer, t and x symbolize time and position, respectively  
(244). These above equations represent a planar geometry of one-dimensional diffusion. 
Similar equations are also available for thick slabs, cylinders, and spheres (243,244). 
Chemically controlled mechanism includes both erodible and pendant chain systems. Erodible 
system is controlled by polymer degradation such as PLGA, PLA, and polycaprolactone 
(PCL). These polymers display simultaneous degradation of entire matrix or could erode from 
surface through core as in the case of polymers made of poly (orthoesters) and polyanhydrides 
(bulk verses surface degradation). It must be noted that in nano-matrices such as MNPs, the 
domain size of crystallization is restricted and water diffusion distance is limited, thus 
polymer degradation is accelerated (245). On the other hand, in pendant chain systems, the 
release is controlled by the enzymatic and hydrolytic degradation of chemical bonds between 
drug molecules and polymeric carrier (241). Biodegradable polymers such as polyesters, poly 
(amino acids), polyamides and polysaccharides discharge drug by degradation of bonds 
(amide, hydrazine and ester) in their backbones (211,212).  
The solvent-controlled release consists of two types: osmosis-controlled and swelling-
controlled release (243). Osmosis-controlled release usually occurs with highly soluble drugs 
that are enclosed by semi-permeable membrane. This mechanism is similar to diffusion except 
that water flows from outside the polymeric carrier to the core (low to high drug 
concentration) causing a build-up of osmotic pressure, which results in rupture of the system, 
and consequently drug release is accomplished (240). At constant concentration gradient, this 
mechanism illustrates zero-order release (205), and the models are anticipated from an 
irreversible thermodynamics and the Kedem–Katchalsky analysis (249). The rate of drug 
release can be written as:  
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!"!"   =    !!   𝐿𝑝  σ  c  Δπs                                                                                             (Eq. 2-4)                                     
Where, A is the cross sectional area, δ thickness of the device, Lp, a permeability coefficient, 
σ, a reflection coefficient, c, drug concentration, and Δπs is the osmotic pressure of water. The 
second type of solvent control release, swelling-controlled, occurs when glassy hydrophilic 
polymer systems are surrounded with aqueous solution. Movement of water leads to volume 
expansion. Two moving interfaces are accompanied in the expansion: swelling interface 
moving inwards and polymer interface moving outwards via the contacting water (241). Both 
diffusion and chain relaxation rate of polymers determine the degree of release (Fickian or 
non-Fickian diffusion). This system is indicated as Stefan or moving boundary problem, 
where diffusion (Eq. 2-3) can be solved with moving boundary conditions at two fronts. Refer 
to (241,250,251) for further details on polymer swelling-controlled modeling.   
The Stimuli-controlled drug delivery system uses stimulus or pathological changes occurring 
in target site as triggers. Stimuli could be either intrinsic - local within the targeted area such 
as changes in pH, up-regulated enzymes or redox potential; or extrinsic-induced externally at 
desired region such as temperature, magnetic field, ultrasonic waves, or light (252,253). These 
carriers are known for target-specific drug delivery. Solid tumour tissues, for instance, exhibit 
weaker acidic pH and higher redox potential than normal tissues (71,254) pH-sensitive linkers 
where developed as a result for more accurate controlled release.  
Although one mechanism may be more dominant to a specific nanocarriers system, multiple 
mechanisms may contribute to the drug release. The relationship between geometry on release 
patterns and drug dissolution is the key in shaping the mathematical Model (207). Enormous 
models have been developed and applied to describe the release mechanism of various nano 
vehicles systems. For polymeric coated MNPs, five main models will be discussed which are 
believed to be most applicable from literature.   
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2.10.1 Korsmeyer–Peppas model 
Korsmeyer et al. derived a relationship describing drug release from a polymeric system (Eq. 
2-5) (256).  
!"!!   = 𝐾𝑡𝑛                                                                                                               (Eq. 2-5) 
Where, Mt / M∞ is a fraction of drug released at time t, K is the release rate constant which 
incorporate the geometric and the structural characteristics of the drug form, n is the release 
exponent. The model was widely accepted due to its simplicity and applicability to different 
release kinetics. It is used when release mechanism is not fully known or if multiple types of 
mechanisms are involved in the system (257) . Drug Release data were fitted to the 
Korsmeyer-Peppas model to observe the fitted mechanism of the system and the release 
exponent became the indicative of system mechanism for cylindrical shaped matrices as 
described in table 2-3.   
Table 2-3: diffusional release mechanisms interpreted from polymeric films according to 
exponent of release (255) 
Exponent of release (n) Mechanism of drug transport Rate as a function of 
time 
0.5 Fickian diffusion t -0.5 
0.45 < n = 0.89 Non -Fickian drug transport t n-1 
n = 0.89 Case II transport release Zero order drug 
release 
n > 0.89 Super case II transport t n-1 
2.10.2 The Huguchi model 
The first mathematical model designed to explain drug release from a matrix system came into 
existence in 1961 by Huguchi (258). It’s a geometry dependent model initially used to simply 
fit release data, then the so-called Huguchi equation expanded to include different geometrics 
and porous systems (259,260). The classical model expression (Eq. 2-6) is obtained with the 
following assumptions (241,255): i) drug solubility is much less than the initial drug 
concentration which allow using pseudo steady state approach, ii) the drug diffusion is one 
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dimensional, meaning edge effects are negligible, iii) particles size of drug is much smaller 
than the system’s thickness, iv) the polymer swelling and/or dissolution is neglected, v) 
coefficient of drug diffusion is constant, and lastly vi) perfect sink condition exist and are 
maintained in the release environment.  
𝑄 = 𝐴   𝐷  𝐶!   2𝐶! − 𝐶!   𝑡                                                                                      (Eq. 2-6)                                
Where, Q is cumulative amount of drug released at time t per unit of surface area A, D is the 
drug diffusion coefficient (diffusivity of drug in matrix), C0 and Cs are the initial 
concentration and the solubility of drug in polymer matrix, respectively. Although equation 5 
cannot be used for most controlled drug release systems, it can be used to analyze the release 
profiles to provide conclusion about the mechanism and it can sometimes be modified 
accordingly. For instance, when the cumulative depletion of drug in the system is reached 
(voiding first assumption with drug solubility being higher than its concentration), and for 
planner matrix with release occurring though pores in the system, the dissolution rate can be 
studied via the adjusted Huguchi expression (Eq. 2-7) (255)   
𝑄 = 𝐴   𝐷𝛿𝜏   𝐶!   2𝐶! − 𝛿𝐶!   𝑡                                                                                  (Eq. 2-7)                     
Here, δ represents porosity of the matrix; τ is the tortuosity, while Q, A, Cs, and C0 denote the 
same meaning described above. The Huguchi model and its adjusted forms can be used to 
describe to many types of pharmaceutical dosage forms such as matrix tablets with water-
soluble drugs and transdermal systems (259).  
2.10.3 Hixson–Crowell model 
Hixson-Crowell model describes the release from a system in which surface area and diameter 
of the matrix is changing (261). The tablet or the particle’s surface area is proportional to the 
cube root of its volume assuming uniformly sized particles as recognized by Hixson and 
Corwell in 1931. Their derived equation is as follows:  
𝑊!!! −   𝑊!!! = 𝜅  𝑡                       (Eq. 2-8) 
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Where, W0 and Wt are the initial and the remaining amount of drug in the pharmaceutical 
dosage form at time t, respectively. 𝜅 is the rate constant for Hixson-Crowell rate containing 
the surface-volume relation (255,261,262). After dividing by W01/3, F=1− (Wt/W0) represents 
the drug dissolved fraction at time t and k is the release constant. Hixson-Crowell model can 
be applied to dosage forms where the dissolution happens in planes that are parallel to the 
drug surface in such a way that the initial geometry is constant throughout process time (263).    
2.10.4 First order model 
Noyes and Whitney first proposed this model in 1897 (264), as the following equation:  
!"!" = 𝐾(𝐶𝑠 − 𝐶𝑡)                                                                                                    (Eq. 2-9) 
It describes the absorption and elimination of drug, where dc/dt represent the rate of change in 
drug concentration, k is the rate constant applied to the concentration gradient (Cs – Ct) 
between the liquid layer close to the solid membrane and the surrounding bulk liquid (262). 
This equation as explained by Noyes and Whitney have the concept similar to the diffusion 
model in the case that there is no change in of the solid shape. Meaning the surface area are 
constant throughout the dissolution process. This might be not the case for degraded polymer 
surfaces. As the size of the particles decrease to nano-range, polymer degradation becomes 
less significant in release mechanism due to the short diffusional path (265). Eq. 2-9 can be 
re-written as: 
log𝐶 = log𝐶! − !"!.!"!                                                                                            (Eq. 2-10) 
Where, C0 is the initial concentration of loaded drug and k is the first order constant.  
Plotting the data according to Eq. 2-10 for log cumulative of drug remaining verses time 
reveals a straight-line relationship (first order) with a slope of –k/2.303 (255).  
Application of this model appears in pharmaceutical dosages having porous matrices loaded 
with highly soluble drugs (266).  
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2.10.5 Baker and Lonsdale 
This model was derived from the Higuchi model by Baker and Lonsdale in 1974. It portrays 
drug release from spherical matrices as presented by the following expression (267):  
!!    1 − 1 −    !!!! !! −    !!!! =    !  !!!!"!  !!!!!                                                         (Eq. 2-11)           
Where, Mt is the amount of drug released at time t, whereas M∞ is amount released at infinite 
time. Dm, Cms are the diffusion coefficient and drug solubility in the polymer matrix, 
respectively. While r0 represent the radius of the matrix and Co is the initial concentration of 
drug (267). When the matrix is not homogenous, meaning factures or capillaries are existent 
and contribute significantly to the release profile, Seki et al. (268) modified Eq. 2-11 to Eq.2-
12 where Df and Cfm are the diffusion coefficient and the drug solubility in the liquid 
surrounding the matrix, respectively. The added terms 𝜏 signify the tortuosity factor in the 
capillary system and the 𝜀 is matrix porosity which can be found by Eq. 2-13 where 𝜀! is the 
initial porosity and K is drug specific volume (269).   
!!    1 − 1 −    !!!! !! −    !!!! =    !  !!!!"!  !!!!!! t                                                (Eq. 2-12) 
𝜀 =    𝜀! + 𝐾𝐶!                                                                                                        (Eq. 2-13) 
When the established conditions are met, the equation on left side will be in linear relationship 
to time as the following:  
!!    1 − 1 −    !!!! !! −    !!!! =   𝑘t                                                          (Eq. 2-14) 
On a graphic representation k corresponds to the slope (270) and this Baker and Lonsdale 
model can be applied in linearizing release data from microcapsules and microspheres 
pharmaceutical formulations (255,271,272).  
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2.10.6 Weibull model 
Weibull model is an empirical model developed by Weibull in 1951(272). It successfully 
befits many dissolution/release curves and had been applied in many dissolution processes  
(272,273) . When it is used in dissolution from pharmaceutical dosage forms, it is expressed 
by: 
𝑚 = 1− exp − 𝑡−𝑇𝑖 𝑏𝑎                                                                                         (Eq. 2-15)          
 Where, m is the accumulated released drug in media at time t and the scale parameter, 𝑎, 
describes the time scale of the process. The location parameter, Ti, is the lag time before 
dissolution/release is started, and is zero in most of curves fitting. The shape parameter, b, 
donates the shape of the dissolution progression curve in terms of three cases. When b=1 (case 
1), the curve is a normal exponential. When b>1 (case 2) the graph represent a sigmoid, S-
shaped, with upward curvature and a turning point is followed. Lastly, graph would have a 
parabolic shape with a steeper initial increase than b=1 followed by a consistent exponential 
curve when b<1 (case 3) (272) . Weibull equation can be rearranged to fit release data as a 
linear function for a log-log of  − ln 1−𝑚  verses time plot as follows:  
log −ln   1−𝑚 = 𝑏 log 𝑡 −   𝑇! − log𝑎                                                      (Eq. 2-16) 
Here, the b is found from graph slope and is obtained from the ordinate value (1/a) at t=1. This 
model has been criticised due to the fact that it’s an empirical and not a fundamental equation 
(274,275). Some deficiencies include that it doesn’t incorporate any parameter related to the 
intrinsic dissolution rate of drug, its inability to characterize the kinetic properties of 
dissolution, and its limitation of use in vivo and vitro correlations.  
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2.11 Conclusion  
MNPs emerging in recent medicine are notably accelerated in the past decade. The 
development of these nanoparticles with variety of formulations is fascinating for both 
imaging and therapeutics. Particularly in this paper, we reviewed the use of MNPs as drug 
carriers for their great potential in targeted delivery and cancer treatment. Targeting ability 
and biocompatibility can be improved though surface coating and have been investigated 
enormously in recent studies. Coating provides a mean to alter the surface features of MNPs 
including physical characteristics and chemical functionality. Coating is chosen with extreme 
care to fit the desired surface characteristics for a specific biomedical application. More 
particularly, the use of biocompatible polymers to coat magnetic cores have great advantages 
such as preventing aggregation, increase colloidal stability, evades nanoparticles uptake by 
RES, and can provide a surface for conjugation of targeting ligands such as peptide and 
biomolecules with high affinity to target cells. Great efforts to bring MNPs from lab testing 
stage to clinic are needed to understand their physicochemical properties and how they behave 
in-vivo, which resulted in few of them to exist in the market today. Although magnetic 
nanoparticles have not yet fully reached their optimal safety and efficiency due to the 
challenges they face in-vivo, their shortcomings can be overcome through improvement of 
magnetic-targeted carrier by pre-clinical trials and continuous studies. 
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CHAPTER 3 
3 Synthesis and Characterization of Dual Stimuli Responsive 
Glycol Chitosan-Fe3O4 Core-Shell Magnetic Nanoparticles for 
Controlled Delivery of Progesterone 
 
3.1 Graphical Abstract 
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3.2 Abstract 
Magnetic nanoparticle, such as superparamagnetic iron oxide nanoparticles (SPIONs), have 
been extensively studied as therapeutic and diagnostic agents due to their remarkable 
characteristics including biocompatibility, bioselectivity, prolonged circulation, and chemical 
stability. The aim of this study was to develop an effective polymeric-metallic hybrid 
nanoparticles coated with novel glycol chitosan polymer (GC) and loaded with progesterone. 
The crystalline nanoparticles were characterized by X-ray diffraction (XRD), Fourier 
transform infrared (FTIR) spectroscopy, transmission electron microscopy (TEM), scanning 
electron microscopy (SEM), thermo-gravimetric analysis (TGA), and vibrating sample 
magnetometer (VSM). Spherical-like superparamagnetic nanoparticles, in the size range of 
10-20 nm, with properly designed GC coating were fabricated. Progesterone release from 
glycol chitosan hybrid magnetic nanoparticles was examined and investigated through several 
mathematical models. Progesterone release kinetics was demonstrated to differ significantly 
with small changes in the pH environment, where glycol chitosan-altered magnetic 
nanoparticles (SPION-GC) exhibited swelling at pH 6.5 and shrinking at pH 7.4.  Moreover, 
MTT assay of C3H10T1/2 cell line cultured with SPION-GC indicated biocompatibility of the 
magnetic nanoparticles. Polymeric-metallic hybrid nanoparticles have shown to be a 
promising potential nanocarriers system for controlled drug delivery applications.  
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3.3 Introduction  
Magnetic nanoparticles are rapidly growing in expansive fields of biomedical applications, 
particularly in drug delivery, magnetic resonance imaging (MRI), gene delivery and tissue 
engineering. They have gained great attention in recent years mainly due to their magnetic 
properties and their ability to function at both cellular and molecular levels (1–3). Magnetic 
nanoparticles (MNPs) have many particular physical and biological features including, but not 
limited to: biocompatibility, , injectability, high magnetic flux density, and small particle size 
distribution (1,4,5). In drug delivery, some of the main advantages of MNPs are their 
capability to integrate drug payloads with different solubility, the improvement in the 
longevity and stability of the therapeutics in blood circulation, their ability to be modified 
according to their surface chemistry for specific cell targeting, and the ability to regulate 
therapeutic release through unique mechanisms (3,6,7). In addition to the utilization of MNPs 
as drug vehicles, their properties allow them for multifunctional therapeutics. Magnetic fluid 
hyperthermia (MFH), for instance, is a heat treatment for cancer that takes the advantage of 
the fact that cancerous cells are more sensitive to heat than normal cells and the unique ability 
of MNPs to self-heat in an external magnetic field (3,8). This key feature of hyperthermia 
combined with their high specific absorption rate due to the nano-size of the drug delivery 
system particles and high cellular selectivity through particle surface modification present a 
promising treatment for cancer and other diseases with minimized systemic side effects 
existing in current treatments such as chemotherapy and radiation (8,9).  
Superparamagnetic iron oxide nanoparticles (SPIONs), a main class of MNPs, were developed 
in this study for their attractive properties and promising outcomes. Their high magnetization 
in an AC magnetic field, which demolish completely once the field is removed provides them 
with opportunities not only in targeted drug delivery and hyperthermia, but also in MRI 
applications (4,10). Their main advantages are biodegradability, ease of synthesis, chemical 
stability, less sensitivity to oxidation, and biocompatibility, recyclability by iron metabolism 
through normal biochemical pathways and their enhanced permeability and retention (EPR) 
effect (1,2,11). SPIONs effectiveness is strongly dependent on the particle dimensions, thus 
controlling a monodisperse size distribution of the particles is very crucial (12–14). A size 
between 10 to 100 nm was reported to be the most efficient for SPIONs parenteral 
administration (13,14). Nevertheless, due to magnetic dipole-dipole interactions, high surface 
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energy and large surface area-to-volume ratio, MNPs tend to agglomerate. Obtaining stable 
and resistant-to-aggregation magnetic colloidal suspension can be achieved through surface 
modification, which creates an electrostatic repulsion between the particles in an effort to 
attain close to equilibrium condition between attractive and repulsive forces (2). Numerous 
studies on surface coating of SPIONs have been performed such as inorganic materials (silica 
(15,16), gold (17,18)), liposomes (19), polymers (Dextran (20–22), polyethylene glycol (PEG) 
(23,24), alginate (25), chitosan (26–28), and others polymers (14)). Moreover, these coatings 
provide further functionalization by attaching various functional groups (carboxylates, sulfates 
and phosphates (29)) and/or targeting biological ligands.  
Chitosan, deacetylated chitin, is a naturally existing polymer with abundant functional groups 
in its backbone structure (30). Although it has been a suitable coating material for iron oxide 
nanoparticles, its application is limited because of its poor solubility. Its deacelyated form is 
only soluble in organic acids at low pH (31) or by modifying the degree of its acetylation to 
about 50%, in which the free amine-containing residues are reduced (30,32). In this study a 
very novel polymer derivative is used, glycol chitosan (GC), as the coating material for 
SPIONs of ferrite nanocrystals of magnetite (Fe3O4). GC is a self-assembled chitosan 
derivative conjugated with ethylene glycol branches. It is fully soluble in neutral and acidic 
pH values due to the glycol branches that aid in increasing the steric stabilization and the 
aqueous solubility (32).  Glycol Chitosan (poly β(1-4)-glucopyranosamine) is from the family 
of cationic hydrophilic polysaccharides, which consist of Nacetyl D-glucosamine and D-
glucosamine residues joined by αβ (1-4) (glycosidic) linkage (33). This polymer captured a lot 
of attention in biomedicine applications such as wound dressings, scaffolds for tissue 
engineering, and drug delivery carriers due to its favourable features, which are believed to be 
because of its free amine groups present in its backbone (33,34). Scheme 3-1 illustrates the 
structure for GC in comparison with Chitosan. The amine group is left unaffected after the 
modification of chitosan to glycol chitosan unlike other chitosan derivatives. This amine 
group allows for alteration to GC, and attaching functionality groups (succinyl, 
dicarboxymethyl, polyethylene glycol and carboxymethyl) for targeted drug delivery, while 
preserving the favourable biological interactions (33,35). Previous studies used GC as the core 
material for nanoparticle self-assembled fabrication. It is widely used as anti-cancer drug 
carrier (36–38) and as a carrier for many hydrophobic drugs and genes (38–40). However, 
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research has rarely touched on its application as a coating material for SPIONs. In only one 
study, Inbaraj et al. assessed the antibacterial activity of GC-coated iron oxide nanoparticles 
(41).  
 
Scheme 3-1: Chemical structure of chitosan (a) and glycol chitosan (b) 
Progesterone is used in this study as the model active pharmaceutical ingredient (API) for 
encapsulation in the uniquely modified GC-SPIONs nanoparticles. It is a 21 carbon 
hydrophobic steroid hormone with water solubility of 3.79× 10-5 M, produced in the ovaries, 
adrenal glands and Leydig's cells (42–44). Progesterone, known as the female hormone, plays 
an important role in the menstrual cycle and during pregnancy and it has vital functions, such 
as being anti-mineralocorticoid and anti-androgenic agent (43). Progesterone structure is 
presented in Scheme 3-2  (45). Interestingly, progesterone showed promising results in many 
studies as a treatment for prostate hyperplasia, which leads to cancer in men (46), it affects 
sleep patterns and erectile function (47), and it has positive effects in the neurotransmission 
system and brain injuries recovery (48–50). 
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Scheme 3-2: chemical structure of progesterone 
The objective of this paper is to comprehensively examine the potential application of GC-
coated SPIONs as a carrier for controlled delivery of progesterone. The suggested inorganic-
polymeric hybrid nanoparticles were developed for the aim of designing a dual responsive 
drug carrier system. The effects of pH and magnetic field were investigated due to the 
presence of magnetic core as well as the pH-responsive glycol chitosan. The kinetics of 
progesterone release was mathematically modeled at different environmental conditions for 
optimization of the drug release rate.  
3.4 Materials and Methods 
3.4.1 Materials  
The chemicals used in this study were analytical grade and used as received without further 
purification. The ferrous (II) sulfate hepta-hydrate (FeSO4.7H2O) was purchased from Sigma-
Aldrich (St. Louis, MO), MW =278.01, Reagent Plus®, ≥99%). Progesterone (MW= 314.46, 
≥99%, mp=128-132 oC), phosphate buffered saline tablets, dialysis kit (Pur-A-Lyzer Mega 
12000) with a membrane type of regenerated cellulose, and Glycol Chitosan (MW = 250,000, 
≥60% (titration) with degree of polymerization ≥400, from crystalline) were purchased from 
Sigma (St. Louis, MO). Phosphate buffer saline tablets were dissolved in 200 mL of deionized 
water to yield 0.01M phosphate buffer, 0.137 M sodium chloride, and 0.0027 M potassium 
chloride, pH 7.4 at 25oC. Ammonium hydroxide (MW: 35.05 g/mol, 28 - 30% assay) was 
obtained from VWR (2360 Argentia Rd.). An Incubating Mini Shaker (120 V, 5 amps, 450 
watts) and Ceramic hot plate Stirrer were bought from VWR international. Deionized water 
and essential glassware and apparatus were used from the laboratory.  
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3.4.2 Synthesis of bare and GC-coated SPIONs 
The synthesis technique used to prepare the magnetic nanoparticles is a modification of the 
co-precipitation method described by Xia et al. (51, 52), which was reported by Ragab et. al. 
(45) . Instead of using two iron salts which are ferrous and ferric chloride, the commonly used 
in co-precipitation synthesis, only one type of salt was used and nitrogen purging is 
substituted with atmospheric conditions. These modifications provide easier and less 
expensive method of synthesis while maintaining the magnetic nanoparticles’ properties 
unchanged (45). The synthesis ran according to the following chemical reactions: 
 
Fe2+ + 2 OH- à Fe(OH)2                                    Eq. 3-1 
4 Fe(OH)2 + O2 à 4 FeOOH + 2 H2O                        Eq. 3-2 
FeOOH + 2 Fe(OH)2 + 5 OH àFe3O4 + 5 H2O + O2              Eq. 3-3 
Batch synthesis of 1.396 g of the iron precursor FeSO4·7H2O were dissolved in 50 mL distilled 
water under continuous magnetic stirring using hot plate stirrer (VWR International, 
Mississauga, ON) for 30 minutes at 40 oC, where color is changed from clear solution to 
yellow/green. Alkaline solution (20 ml of Ammonium hydroxide) is then added slowly to the 
mixture, where a dark green/black solution is obtained. At this point stirring is continued and 
the temperature is immediately increased to 90 oC and is covered for additional 90 minutes. 
After the mixture has cooled to room temperature, the prepared precipitate of SPIONs was 
separated from the supernatant using an external strong magnet and the supernatant was 
removed with a pipette. Ten milliliters of distilled water was added and mixed well with the 
SPIONs precipitate. The water was removed using a magnet for separation and the 
supernatant was removed using a pipette as well. SPIONs were washed three times with 
distilled water (10 ml each) and a fourth time with ethanol (5ml wash) using the same 
procedure. The precipitate was then manually collected from the reaction mixture with the 
external magnet and is left to dry at room temperature for 24 hours or by vacuum oven at 80 oC 
for one hour.  
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In preparing GC-coated SPIONs, same procedure of bare- SPION synthesis was performed 
followed by a post coating step of glycol chitosan polymer. Different amounts of GC were 
dissolved in 100 ml of distilled water by magnetic stirring. The dried SPIONs are then added 
to the mixture at room temperature with continuous stirring for 24 hours.  
3.4.3 Preparation of progesterone loaded GC-coated SPIONs 
The progesterone loaded magnetic nano-aggregates coated with glycol chitosan were prepared 
with different concentrations of progesterone solution (0.25x10-3 mmol, 0.50x10-3 mmol, and 
0.75x10-3 mmol). The progesterone solution was prepared by dissolving different amounts of 
progesterone in 1 mL of acetone in a glass vial.  SPIONs dispersion was prepared by mixing 
100 mg of SPION in 100 mL of distilled water with continuous mixing for half an hour. 
Progesterone solution was then added to the SPIONs solution and vigorously mixed for 24 
hours at room temperature. The precipitated magnetic nano-structures were washed with 
ethanol using same procedure described above and then dried at room temperature.  
 
3.4.4 Magnetic and Structural characterization of bare and GC-coated 
SPIONs  
X-ray Diffraction (XRD) Analysis: The crystallite structure of Fe3O4 nanoparticles was 
investigated using XRD powder analysis (Rigaku-Miniflex, The Woodlands, TX,) and the 
samples were exposed to radiation CuKα, 40 KV, 20 mA at a wavelength of 1.54 Å. The 
diffracting angle 2-theta covered from 15° to 65° with a 0.02° step size  (45, 53, 54).  
Fourier Transform Infrared (FTIR) Spectroscopy: A Bruker vector 22 spectrometer controlled 
by OPUS 5.1 analytical software was used to obtain the FTIR spectra of the SPIONs samples 
in a powder state. The powder was scanned by an attenuated total reflectance (ATR) with 
resolution of 4 cm-1 and total scans of 32. The samples were scanned between 4000 -500 cm-1. 
Transmission Electron Microscopy (TEM): Philips CM10 Transmission microscope was used 
with magnification range of 18× to 450,000×; Resolution (objective lens): 0.5nm/5.0å (point), 
0.34nm/3.4å (line); and accelerating voltage range of 40kV to 100kV. ImageJ software was 
used to analyze the particle size. A total of 200 particle diameters for each sample were 
measured to obtain the particle size distribution and. There samples for each GC coated 
SPIONs was analyzed by ImageJ for accuracy.  
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Scanning Electron Microscopy (SEM): The surface morphology was examined using SEM 
(Hitachi High-Technologies GmbH, Germany).  Before examining the samples, they were 
prepared on aluminum stabs then sputtered with gold and measured at an accelerating voltage 
of 20 kV coupled with energy dispersive X-ray spectroscopy (EDX) for elemental analysis. 
Thermo-Gravimetric Analysis (TGA): The weight percentage of GC attached to the SPIONs 
surface was analyzed by TGA with a range of 25 to 600 °C in air at a ramp rate of 
10 °C min− 1. The original and the first derivative results were obtained.   
Powder Magnetization (Vibrating Sample Magnetometer, VSM): The magnetic properties 
were measured using a vibrating sample magnetometer (LakeShore cryotonics 7407, 
Westerville, OH). The magnetic properties of nano-aggregates samples were studied at 
moment measure range of 10-7 to 103 emu, 0.05% full scale with field accuracy. All the 
magnetization measurements were carried out at room temperature under a maximum field of 
10 kOe. 
 
3.4.5 Drug loading and encapsulation efficiency 
Drug loading is defined as the amount of drug encapsulated inside the nanoparticles per unit 
mass (45). SPIONs were loaded with various amounts of progesterone, which was 
predetermined according to its solubility in aqueous solution (5, 10, 15, 25, 50, 75mg). The 
concentration of progesterone encapsulated was determined by dissolving a known amount of 
nano-aggregate samples in ethanol. The supernatant taken after 24 hours of magnetic stirring 
with SPIONs was measured with UV spectrometer (manufacturer) to obtain a quantitative 
amount of the drug discharged from the nanoparticles. The ratio of progesterone recovered in 
SPIONs to the total amount of drug loaded is the encapsulation efficiency. Each measurement 
was repeated in triplicate per sample. Eq. 3-4 and Eq. 3-5 were used in the calculation (51, 
52). 
 𝐄𝒏𝒄𝒂𝒑𝒔𝒖𝒍𝒂𝒕𝒊𝒐𝒏  𝒆𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒄𝒚   = 𝒂𝒎𝒐𝒖𝒏𝒕  𝒐𝒇  𝒅𝒓𝒖𝒈  𝒆𝒏𝒄𝒂𝒑𝒔𝒖𝒍𝒂𝒕𝒆𝒅𝒕𝒐𝒕𝒂𝒍  𝒂𝒎𝒐𝒖𝒏𝒕  𝒐𝒇  𝒅𝒓𝒖𝒈     𝒙  𝟏𝟎𝟎                    Eq. 3-4 
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𝑫𝒓𝒖𝒈  𝒍𝒐𝒂𝒅𝒊𝒏𝒈   = 𝒘𝒆𝒊𝒈𝒉𝒕  𝒐𝒇  𝒅𝒓𝒖𝒈  𝒆𝒏𝒄𝒂𝒑𝒔𝒖𝒍𝒂𝒕𝒆𝒅𝑾𝒆𝒊𝒈𝒉!  𝒐𝒇  𝒅𝒓𝒚  𝒏𝒂𝒏𝒐𝒑𝒂𝒓𝒕𝒊𝒄𝒍𝒆𝒔     𝒙  𝟏𝟎𝟎                                   Eq.3-5 
 Table 3-1: Effect of the initial progesterone concentration (w/w) on the drug loading and 
encapsulation efficiency 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.6 In-vitro cytotoxicity study of GC-coated SPIONs 
The cytotoxicity of the progesterone-loaded GC-SPIONs was evaluated using 
C3H10T1/2   mouse mesenchymal cell line, where metabolic cell activity was measured by 
MTT assay; a colorimetric measure of the mitochondrial activity. Two independent cell 
culture studies were performed: time-course and dose-course studies. In the dose-course study, 
cells were pre-cultured for 24 hours after seeding at a density of 8,000 cells/well in 96-well 
plates. Afterwards, C3H10T1/2 were treated with various concentrations of progesterone 
encapsulated nanoparticles (25, 50, 75, and 100 µg/mL) with various coating concentrations 
of GC in the presence of 10% FBS. After 48 hours of incubation at 37oC, MTT solution 
(5 mg mL−1 MTT in phosphate buffer solution, pH 7.4) was added to each well and absorbance 
Initial drug 
loaded 
concentration  
(mg / ml) 
Progesterone 
concentration 
(w/w, mg drug / mg 
nanoparticles) 
Drug loading 
(%) 
Encapsulation 
efficiency 
(%) 
0.5 1 12.40±0.35 34.02±3.54 
1 2 15.90±0.26 24.52±1.29 
2 6 19.25±0.52 19.25±1.73 
2.5 10 19.77±0.71 18.51±1.43 
5 20 27.17±0.98 15.17±0.98 
7.5 30 29.54±2.03 9.34±1.35 
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was measured at 570 nm.  The same procedure was used in the time-course study. However, 
one concentration (50 µg/mL) was chosen and cells were treated with progesterone loaded 
SPIONs with different GC coatings concentrations and without GC coating (as a 
control).  Then, MTT absorbance values were measured following 48 hours and 96 hours of 
culture. 
3.4.7 In-vitro release study of GC-coated SPIONs 
In-vitro progesterone release was carried out in a dialysis bag (Pur-A-Lyzer Mega 12000). 
The dialysis bag insured that diffusion occurred only for drug molecules without passage of 
the SPIONs. Scheme 3-3 shows the floating dialyzer setup. For the in-vitro release 
experiment, 15 mg of GC coated SPIONs at different GC coating concentrations (62.6, 125, or 
178.5 mg GC) loaded with 5mg progesterone in 10 mL of the release media was introduced 
into the inner tube of the dialyzer. Progesterone is freely soluble in the media with an addition 
of 0.5ml of acetone and 0.1% of Tween 20. The dialyzer was placed into a 60 mL beaker 
containing the release media. Two release media were used: distilled water or phosphate-
buffered saline (PBS) to compare the release at different pH values, 6.5 and 7.4, respectively. 
The setup was placed at 37°C incubating shaker at 300 rpm in order to prevent the formation 
of unstirred water layer at membrane/outer media interface.  Diffusion was measured by 
sampling 5mL of the outer solution at predetermined time intervals. Fresh solution of distilled 
water or PBS solution was replaced in the breaker. The samples were measured with UV 
visible spectroscopy at 450 nm maximum wavelength.  
3.5 Statistical analysis 
The experiments were performed in multiple replicates. The data from each replicate was 
calculated independently. The experimental data was presented as mean ± standard deviation 
(SD) and was analyzed statistically by a one-way analysis of variance and the level of 
significance was determined at p < 0.05. 
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3.6 Results and Discussion 
3.6.1 X-ray Diffraction (XRD) 
XRD provides information about the crystalline structure of the synthesized particles, where 
the degree of structure order is identified (53). It was performed in this paper to prove that 
magnetite was in fact produced and that the polymer coating did not affect the magnetite 
crystalline phase. In Figure 1a, The characteristic peaks of inverse cubic spinal structure is 
observed (54,55). According to the literature, iron oxide nanoparticles show sharp prominent 
peaks at 30.5 (220), 35.84 (311), 43.46 (400), 53.90 (422), 57.38 (511) and 62.90 (440) with 
311 peak having the highest intensity (55–57). Figure 1b, shows the standard XRD pattern for 
magnetite obtained from ICCD with card number 00-019-0629. These peaks with similar 
intensities and with the corresponding angles were present in all of the tested samples. This 
indicates that the prepared Fe3O4 by alkaline precipitation corresponded to the pure phase of 
Fe3O4 and that the used synthesis technique was feasible (55). It was also noted that the 
addition of different weight concentrations of GC polymer did not alter the XRD spectrum, 
where the same peaks were present indicating that the spinal structure of Fe3O4 NPs was 
Scheme 3-3: an illustration of the in vitro release setup using dialysis system 
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retained (56). However, the peak intensity of the coated SPIONs appeared to be lower 
compared to the naked Fe3O4 since the amount of naked particles is lower (56).  The width of 
the diffraction peak is related to the size of the crystalline particles; the narrower the 
diffraction peak, the larger the particle size (53). The average particle size of  SPIONs (D) can 
be calculated using Scherrer’s equation (Eq.3-6).   
𝑫 = 𝐊𝛌(𝛃𝐜𝐨𝐬  𝛉)                                                                                                                                                                                                                                             Eq. 3− 6 
Where, K is a constant, λ is X-ray wavelength, β is the peak width of half-maximum and θ is 
the Bragg diffraction angle (54). In this work, the strongest diffraction peak was chosen for 
calculating the diameter of SPIONs. The size was determined using TEM as well for precision 
as presented in Table 3-2. It is clear that particle size increased with polymer coating. TEM 
and XRD results were in good agreement with each other.  
 
  
 
 
                                                                                                         
 
 
 
 
 
 
a) 
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Table 3-2: Effect of GC concentration on the measured particle size data (TEM) and the 
calculated values based on XRD 
Sample code Concentration 
of glycol 
chitosan 
(mmol) 
Concentration 
of Fe3O4 
(mmol) 
Particle size 
(nm, 
Estimated 
from the 
XRD pattern) 
Particle size 
(nm, 
measured 
using TEM) 
Uncoated 
Fe3O4 
0 1.6x10-3 10.31 8.76±2.00 
Fe3O4 - GC 1 0.25x10-3 1.6x10-3 12.71 11.87±3.20 
Fe3O4 - GC 2 0.5x10-3 1.6x10-3 15.68 12.20±2.61 
Fe3O4 - GC 3 0.75x10-3 1.6x10-3 18.41 20.40±3.24 
Figure 3-1: XRD pattern of Magnetite: a) the effect of GC coating on the 
crystalline structure of SPIONs, b) standard XRD pattern of Magnetite (58).  
b) 
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3.6.2 Fourier transform infrared (FTIR) spectroscopy 
 FTIR analysis was performed to confirm that GC had truly coated the Fe3O4 nanoparticles. 
The FTIR spectra in Figure 3-2 prove the interaction between CG and the Fe3O4 nanoparticles. 
The clear broad peak at absorption band 3353 cm-1 could be attributed to the stretching 
vibration of O-H and N-H (58). Also, C-H stretching vibration could be assigned to the peak 
at 2925cm-1. The absorption band at around 1630 cm-1 in the pure GC and the coated samples 
corresponded to the amide bond of the undeacetylated section of GC whereas; this peak was 
absent in the bare SPIONs (data not shown). The small peak at 1544 cm−1 is an indication of 
the N–H bending vibration of the free amine group of the deacetylated section of GC, which 
was more apparent in the pure GC spectrum (56,59). The glycosidic linkage (ether bond) and 
C–N vibrations were illustrated in the absorption bands at 1110 and 1062 cm−1, respectively 
(56,60). The peak at 586 cm−1 only appeared in the coated samples and was absent in pure GC. 
This peak could be assigned to Fe–O stretching vibration of Fe3O4 (45,58,61). The FTIR of 
bare SPIONs contained peaks at 578 cm-1 and at 3401 cm-1 that were attributed to Fe-O and O-
H vibrations, respectively. Shifting in the amide bond peak was observed from 1677 to 1630 
cm-1 in GC/Fe3O4. This shift from a higher energy level to a lower one could indicate that the 
interaction between GC and SPIONs was through a nitrogen atom as suggested by literature 
(62,63). Altogether, these data has proved the coating of SPIONs with GC. 
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3.6.3 Transmission electron microscopy (TEM)  
Figure 3-3 shows the representative TEM images of coated Fe3O4/GC with varied 
concentrations as specified in Table 3-2 and uncoated SPIONs as a control. The 
corresponding histogram of particle size distribution for uncoated and GC coating 
concentration of (0.5 ×103 mmol), determined by image analysis using the count of 200 
particles, was illustrated in Figure 3-4a and b.  Spherical-like agglomerated SPIONs was 
Figure 3-2: FTIR spectra of Glycol chitosan (GC), GC-coated magnetic nanoparticles, 
and uncoated magnetite 
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clearly observed in Figure 3-3a as expected, due to the magnetic dipolar forces and van der 
Waals forces between the nanoparticles. As shown, Fe3O4/GC maintained nearly spherical 
shape similar to that of bare SPIONs with wider separation of particles compared to uncoated 
particles. This means that the forces between the particles had likely decreased due to the 
surface modification with GC coating. Particle size was found to increase with higher coating 
concentration starting at 8.76 nm for uncoated and ending at 20.4 nm for Fe3O4/GC-3 as 
detailed in Table 3-2. Particle size measurements by TEM corresponded well with particle 
size analysis by XRD. The increase in particle size may indicate that GC was evenly 
surrounding the core SPIONs in a core/shell structure. Moreover, the particle size distribution 
had increased as GC layer was added.  Uncoated SPIONs tend to show poor distribution 
(skewed to the right wide distribution), while Fe3O4/GC shows better distribution (normal 
distribution with narrower distribution range). This may reflect a lower degree of aggregation 
with GC coating in comparison to bare SPIONs.  
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Figure 3-3: TEM images illustrating the effect of polymeric GC coating on bare 
SPIONs: (a) uncoated SPIONs (b) Fe3O4/GC-1 (c) Fe3O4/GC-2 (d) Fe3O4/GC-3 
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Figure 3-4: Histogram of particle size distribution: A) for uncoated SPIONs with 
average size diameter of 8.76nm and B) coated SPIONs with the middle used 
concentration of GC  
3.6.4 Scanning electron microscopy (SEM)  
SEM images of magnetic SPIONs nano-aggregates are presented in Figure 3-5. Samples of 
uncoated SPIONs (Figure 3-5a) and three different GC-SPIONs coating concentrations were 
examined. The presented images unveiled that the prepared iron oxide powder encompassed 
uniformly aggregated spherical primary nanoparticles. According to literature, spherical drug 
vehicles are much more favored in drug delivery application, especially in the nanoscale (64). 
Bare SPIONs tend to be clustered in groups. The addition of GC layer on the nanoaggregates 
did not affect the particle morphology; however, the clustering tends to loosen up as GC 
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coating was introduced and decreased gradually as thicker GC coating was used. In fact, it is 
apparent that with Fe3O4/GC-3 (Figure 3-5d), the nanoparticles were much more separated 
and homogenously distributed. In addition, it can be observed that the individual particles 
were enlarged because of the GC coating of the SPIONs starting with their particle size of 
8.76 nm. Moreover, SEM images had confirmed that the overall particle layout became denser 
as the coating concentration increased.  
 
  
Figure 3-5: Scanning electron micrograph (SEM) images for different magnetic 
nanoaggregates. Effect of polymeric composition of GC on their morphology: a) 
uncoated SPIONs b) Fe3O4/GC-1 c) Fe3O4/GC-2 d) Fe3O4/GC-3 
3.6.5 Thermo-Gravimetric Analysis (TGA)  
TGA graphs in Figure 3-6 illustrate the surface adsorption of GC on SPIONs. TGA 
measurement was preformed to confirm the GC coating formation and determine the amount 
of polymer associated with the SPIONs.  It could be observed that the coating rates for 
uncoated, Fe3O4/GC-1, and Fe3O4/GC-3 were 96.02%, 89.17%, and 90.46%, respectively. The 
results clearly showed that the coated nanoaggregates were significantly different from the 
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bare SPIONs, and both Fe3O4/GC-1 and Fe3O4/GC-3 displayed a similar weight loss profile 
below 400°C. The initial stage of weight loss was around 2% for all samples within the first 
200°C, this is most likely related to the removal of adsorbed water, because of surface 
hydroxyl groups, or both as expected in systems containing polymer-coated magnetite 
nanoparticles (65,66). The slight weight loss noticed in bare SPIONs after 200°C is probably 
attributed to the decomposition of amorphous iron hydroxides as confirmed by literature (41). 
A significant gradual weight loss for both of the Fe3O4/GC tested samples was observed above 
180°C with maximum temperature at 252.5°C. This weight loss is likley due to the 
evaporation and the decomposition of the GC coating layer surrounding the nanoaggregates, 
which may demonstrate that a substantial amount of GC, estimated as approximately 10% of 
the SPION weight, was successfully coated on the surface of the Fe3O4 nanoparticles. 
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3.6.6 Powder magnetization  
Power magnetization was studied to determine how the magnetic properties are affected after 
surface modification via GC surface coating. Vibrating sample magnetometer (VSM) is used 
to measure the magnetic properties for uncoated SPIONs and the three coating samples of GC. 
Figure 3-7 exhibits a typical magnetization pattern of bare nanoparticles and GC- Fe3O4. 
Superparamagnetic property is demonstrated, where the hysteresis loops for all samples 
indicates a single-domain magnetic nanoparticle.  Remanence is a measure of the remaining 
magnetization after the driving field is dropped to zero while coercivity is the measure of the 
reverse field needed to drive the magnetization to zero after it had reached saturation. When 
these two values are low, it shows better superparamagnetic property. This is a standard 
property for maghemite and magnetite with diameters between 10-20 nm (67,68). This 
attractive feature allows for their reuse by their ability to demagnetize once the external 
magnetic field is removed. Fe3O4/GC-2 shows a particular superparamagnetic characteristic 
that may surpass that of naked SPIONs as Table 3-3 displays. Fe3O4-GC 1 and Fe3O4-GC 3 
have similar retentivity, yet higher coercivity compared to Fe3O4-GC 2, but not significantly.  
Particles having less than 20 Oe coercitvity are part of the superparamagnetic family as 
termed by literature (69). Thus, the three GC coated samples are confirmed to be 
superparamagnetic. The decrease in superparamagnetic property in Fe3O4/GC-1 and Fe3O4/GC-
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Figure 3-6: TGA profile of GC-coated magnetic nanoparticles and its first derivative graph. 
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3 may be due to the increase in particle size because of the thicker GC layer incorporated. 
This is also evident in the increase of retentivity compared to the naked SPIONs. The presence 
of GC on particles surface lessened their uniformity due to reducing the surface moment, 
which sequentially decreased the magnetic moment of these particles. The measured 
saturation magnetization value for bare SPIONs is 68.98 emu/g, which is closely similar to 
Fe3O4/GC-2 and Fe3O4/GC-3. These values are similar to the reported values in literature 
(66,70).  Nevertheless, Fe3O4/GC-1 showed elevated saturation magnetization at value of 
113.39 emu/g. Altogether, the prepared Fe3O4/GC can provide targeted delivery and ease of 
post-delivery separation. 
 
  
Figure 3-7: Hysteresis curves at room temperature of bare and GC coated SPIONs 
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Table 3-3: Magnetization parameters of glycol chitosan coated magnetic nanoparticles 
compared to the bare magnetic core 
3.7 Evaluation of GC-SPIONs cytotoxicity 
Figure 3-8 shows the dose-course metabolic activity of C3H 10T1/2 cells as determined by 
MTT assay, and values are presented as mean ± SD of triplicates. The uncoated nanoparticles 
did not show any significant difference in metabolic activity in all concentrations except for 
100 µg/mL of progesterone-loaded nanoparticles. For coated nanoparticles, both 25 and 50 
µg/mL demonstrated insignificant decrease, whereas 75 and 100 µg/mL had a significantly 
decreased metabolic activity in comparison to the startup rate but not significant compared to 
the bare nanoparticles. This suggests that the uncoated and unloaded SPIONs do not impose 
any cytotoxicity to the cells and same goes with GC-coated nanoparticles. Nevertheless, when 
the GC-SPIONs are loaded, progesterone could affect cellular activity at the highest tested 
concentrations. The significant decrease at 75 and 100 µg/mL in GC-SPIONs might be due to 
the higher encapsulation rate of progesterone in GC-coated nanoparticles verses the uncoated 
particles. By decreasing the progesterone initial loading, the level of cytotoxicity decreased as 
a function of concentration. Also, the time-course study (Figure 3-9) demonstrated the ability 
of the 10T1/2 cells to grow and function under the treatment of GC-SPIONs. Cells after 48h 
and 96 h were able to grow in a time-dependent manner showing the biocompatibility of the 
Sample code Magnetization (emu/g) Retentivity (emu/g) Coercivity (G) 
Uncoated Fe3O4 68.98 2.54 1.56 
Fe3O4 - GC 1 113.39 7.56 4.84 
Fe3O4 - GC 2 67.88 0.19 0.95 
Fe3O4 - GC 3 68.67 4.97 4.62 
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synthesized particles in-vitro. Overall, results show that the prepared GC-SPIONs are well 
tolerated by C3H 10T1/2 cells.  
  
 
 
 
 
 
 
Figure 3-8: Dose-course of metabolic activity of C3H 10T1/2 cells as determined by MTT 
assay  
 
 
 
 
 
 
 
Figure 3-9: Time-course of the metabolic activity of C3H 10T1/2 cells as determined by 
MTT assay  
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3.8 Progesterone loading and in-vitro Release 
The amount of 5 mg of progesterone (0.1 mg / mg nanoparticles) was chosen as the ideal 
concentration to be encapsulated in the coated SPIONs for all the proceeding studied samples, 
based on the predetermined encapsulation efficiency data.  Encapsulation efficiency was 
calculated to be 34.02±3.54 for this loading ratio. Progesterone is likely to have placed itself 
into the SPIONs highly porous structure. Changing the concentration of glycol chitosan in the 
composite has significantly increased the drug encapsulation efficiencies as shown in Table 3-
4. 
 In fact, Fe3O4/GC-3 encapsulation efficiency was almost doubled compared to naked Fe3O4 
(34.02±3.54 add naked particle values to the table to 63.54±4.65). The increase in the 
efficiency and percentage loading haddecreased when higher concentrations of GC were used. 
This may be due to the saturation of the GC coating, which may have prevented progesterone 
from penetrating though the cross-linked network of the GC structure.  Also, it was indicated 
that progesterone-loading percentage had increased with increasing the surface coating (Table 
3-4). Glycol chitosan is a self-assembled polymeric amphiphile, where the hydrophobic 
moieties are facing towards the core, and the hydrophilic moieties are facing towards the 
solution (30). For this reason GC is freely soluble in water at a wide pH range (71). When GC 
meets the hydrophobic progesterone, they are more prone to form hydrogen bonding with 
other weaker interactions such as hydrophilic/hydrophobic and electrostatic interactions 
(72,73). These bonds are expected to form at the internal surface of GC. Meaning, 
progesterone will be encapsulated into SPIONs and GC core. The more binding sites are 
available, the higher the chance for progesterone molecules to attach to GC (Scheme 3-4). 
This explains why the loading percentage of progesterone has increased with higher 
concentrations of GC coating. 
The release profiles of progesterone from Fe3O4/GC SPIONs at pH 6.5 were depicted in 
Figure 3-10. For all surface modified magnetic nanoparticles, the initial burst release was 
observed within the first 3h with a maximum cumulative release of 5%. This strongly 
corresponds to the release of drug present on the surface of the nanoparticles. Initial burst was 
much better suppressed compared to the uncoated nanoparticles. Fe3O4/GC exhibited sustained 
release behavior for 15 days at cumulative percentages of 64.82%, 30.00%, and 25.50% for 
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Fe3O4/GC-1, Fe3O4/GC-2 and Fe3O4/GC-3, respectively. The release after day 15 had an 
insignificant release rate increase and had reached equilibrium state at day 16.  
 In nanoparticles drug delivery systems, polymer degradation plays an important role in the 
release profile. Since GC is soluble in water it tends to deteriorate faster in solution compared 
to other non-soluble polymers in a shear thinning behaviour. Also, the type of bonds and 
cross-linking of polymer to drug/ nanoparticles greatly influence release rates (73). Moreover, 
combination of both drug diffusion and polymer degradation can play an important role in 
influencing release rates of progesterone remarkably (74). 
 
Table 3-4:Release data containing encapsulation efficiency, loading rates and release 
rate constants for coated and uncoated SPIONs 
 
 
  
  Sample code 
Concentration 
of glycol 
chitosan 
(mmol) 
Progesterone 
encapsulation 
efficiency 
(%) 
Progesterone 
loading 
percentage 
(%) 
Release 
rate 
constant 
at pH 6.5 
(k, day-1) 
Release rate 
constant at pH 
7.4 
(k, day-1) 
Fe3O4 - GC 1 0.25x10-3 35.49±1.84 16.51±2.89 
11.2615±0
.32 
- 
Fe3O4 - GC 2 0.5x10-3 46.82±5.78 31.76±6.21 
9.0170±0.
58 
- 
Fe3O4 - GC 3 0.75x10-3 63.54±4.65 38.23±5.7 
9.0170±0.
58 
14.0973±1.15 
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Scheme 3-4: likelihood positions of H-bonding forming between glycol chitosan and 
progesterone 
 
Figure 3-10: Release profiles of progesterone from variable GC coated SPIONs 
formulations: effect of increasing GC surface coating on Fe3O4 at 5mg progesterone 
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3.9 Study of the kinetics of progesterone release from glycol chitosan 
coated magnetic nanoparticles 
The observed enhancement in cumulative release of progesterone as the concentration of GC 
is lowered can be explained by the hydrogen bonding and hydrophobic interactions present 
between GC and progesterone. At high GC concentration, progesterone tends to attach firmly 
to GC and consequently restrict its permeation through its polymeric networks. Besides, the 
incorporated negatively charged Fe3O4 was attached tighter to the positively charged GC upon 
additional GC concentration, constraining the release even further. Progesterone release 
kinetics was analyzed by fitting the data to the simplifed semi-empirical Korsmeyer-Peppas 
model (Eq. 3-7) (73,75,76) 
𝑴𝒕𝑴!   = 𝑲𝒕𝒏                                                                                                                                                                                                                                                                  Eq. 3-7 
Where, Mt / M∞ is the fraction of drug released at time (t), K is the release rate constant 
(integrates the geometric of the drug form), n is the release exponent that assists in 
determining the best fitted mechanism for the system. This equation is a simplified version of 
the Peppas model where diffusion is assumed to be the main drug release mechanism. 
Peppas et al. (75) explained the controlled delivery of drug release using different geometrics 
and drug vehicles structures. The value of release exponent n was emphasized to describe the 
release mechanism for non-swellable systems with the assumption of having mono-dispersed 
particles under one-dimensional diffusion (Table 3-5) . For spherical particles with 0.5 < n < 
1.0, the model indicates an anomalous diffusion or non-Fickian diffusion (coupled transport), 
as in the case of Fe3O4/GC-1 detailed in Table 3-6, while Fe3O4/GC-2 and Fe3O4/GC-3 
exhibited a Fickian diffusion. TAlthough Peppas model provided an idea about the release 
mechanism, this system does not fully apply to the assumptions made by Peppas et al. For 
example, having a wide size distribution, this can cause significant diffusion acceleration in 
the early stage of release and considerable delay of release towards the end stage. Thus, 
further investigation on drug release behaviour must be conducted for more accurate 
explanation of progesterone release from the Fe3O4/GC nanoparticles.  
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Table 3-5: diffusional release mechanisms interpreted from polymeric films according to 
exponent of release 
 
 Table 3-6: Determination of the drug release mechanism based on the release exponent 
value of progesterone from SPIONs coated with different concentrations of glycol 
chitosan (GC) 
 
3.9.1 Investigation of the release behavior though various mathematical 
models 
Mathematical modeling of composite drug delivery has great value in deepening the 
understanding of the physical mechanisms governing drug release, by determining important 
parameters that impact the release rates. Mathematical investigation of progesterone release 
process was conducted by fitting various validated release models: Baker–Lonsdale, 
Exponent of release (n) Mechanism of drug transport Rate as a function of time 
0.5 Fickian diffusion t -0.5 
0.45 < n = 0.89 Non -Fickian drug transport t n-1 
n = 0.89 Case II transport release Zero order drug release 
n > 0.89 Super case II transport t n-1 
Sample code Peppas fitted equation R2 
Release 
exponent 
Drug 
release 
mechanism 
Fe3O4 - GC 1 
𝑀𝑡 𝑀∞ =   10.587𝑡!.!""# 0.95104 0.5 < n < 
1.0 
Anamolous 
diffusion 
Fe3O4 - GC 2 
𝑀𝑡 𝑀∞ =   9.3258𝑡!.!"!# 0.87711 n ≤ 0.5 Fickian 
diffusion 
Fe3O4 - GC 3 
𝑀𝑡 𝑀∞ =   7.927𝑡!.!"!# 0.87711 n ≤ 0.5 Fickian 
diffusion 
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Korsmeyer–Peppas, Hixon and crowell, Higuchi equation, and first-order equation to the 
manipulated experimental data. Equations of the empirical models are illustrated in Table 3-7 
Correlation coefficients and simulated equations were calculated and compared. Determining 
the best fitting model was carried out though the comparison of the R2 values shown in Table 
3-8. It is clear that Baker–Lonsdale and Korsmeyer–Peppas models best describe the 
progesterone release from Fe3O4/GC nanoparticles as the correlation coefficient is greater than 
0.9690 under all different GC concentrations. In Korsmeyer–Peppas model, the release 
mechanism showed via the n value had the same results compared to the semi-empirical 
Korsmeyer-Peppas found earlier. Fe3O4/GC-1 had an n value between 0.5 and 1.0 representing 
a non-fickian diffusion mechanism, while both Fe3O4/GC-2 and Fe3O4/GC-3 showed fickian 
diffusion mechanism with n ≤ 0.5. Increasing the coating concentration was associated with a 
decrease in the drug release rate for both Korsmeyer-Peppas and Baker–Lonsdale models. For 
example, Fe3O4/GC-1 had a Peppas release rate of 11.2615± 0.3150, whereas Fe3O4/GC-2 had a 
value of 9.0170± 0.5765 
Table 3-7: The empirical mathematical models used to fit progesterone release data 
Mathematical model Equation 
Baker-  Lonsdale model 32    1− 1−    𝑀!𝑀∞ !! −    𝑀!𝑀∞ =   𝑘 
Peppas model 𝑀𝑡𝑀∞   = 2   𝐷𝑡𝛿! ! ! = 𝑎𝑡! ! 
Hixon and Crowell model 𝑊!!! −   𝑊!!! = 𝜅  𝑡 
Higuchi model  𝑄 = 𝐴   𝐷𝛿𝜏   𝐶!   2𝐶! − 𝛿𝐶!   𝑡 
First Order Model 𝑑𝑐𝑑𝑡 = 𝐾(𝐶𝑠 − 𝐶𝑡) 
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Table 3-8: Correlation coefficients values of fitted kinetic models on cumulative release 
curves on Fe3O4/GC 
a. Baker-  Lonsdale model           b. Peppas model,                 c. Hixon and Crowell model 
d. Higuchi model                          e. First Order Model 
3.10 Effect of pH change on progesterone release profile 
The release of progesterone from Fe3O4/GC-3 was investigated at two different values of pH 
release media (6.5 and 7.4). The maximum cumulative release amount of progesterone was 
72.02% at pH 7.4, while the released amount decreased to 30.00% at pH 6.5. However, 
similar release trends were observed for both, where the samples exhibited an initial fast burst 
release followed by relatively slower release till equilibrium was reached (Figure 3-11). 
Nevertheless, for all of the examined samples, an increase in the pH yielded an increase in the 
rate of drug release. These data could be explained by the swelling nature of glycol chitosan in 
accordance with the change in the pH of release medium. Scheme 3-5 demonstrates the two 
possible mechanisms of progesterone permeation both through the pores between the GC shell 
and Fe3O4 core, and through the GC shell itself. 
 
Sample code Concentration 
of glycol 
chitosan 
(mmol) 
 
R2 a   
 
 
R2 b 
 
 
R2  c  
 
R2  d  
 
R2  e  
Fe3O4 - GC 1 0.25x10-3 0.9939 0.9974 0.9362 0.9970 0.9483 
Fe3O4 - GC 2 0.5x10-3 0.9690 0.9743 0.8498 0.9688 0.8601 
Fe3O4 - GC 3 0.75x10-3 0.9690 0.9743 0.8498 0.9688 0.8709 
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Figure 3-11: The effect of pH value on the release profile of the highest concentration of 
GC coated SPIONs (Fe3O4/GC-3)   
 
Scheme 3-5: An illustration for the proposed pH-responsive mechanism of 
Fe3O4-glycol chitosan hybrid magnetic nanoparticles 
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The rigid Fe3O4 core does not swell in accordance with the pH changes. However, the GC shell 
swells or shrinks according to the external pH condition (77). At relatively lower pH value 
(pH 6.5), the GC shell is protonated and swelled to a greater extent. The swollen GC shell was 
expected to block the pores in the GC-Fe3O4 network structure; which explains the lower rate 
of drug permeation at slightly lower pH value. On the other hand, the enhanced rate of drug 
release at pH value 7.4 was attributed to the shrunken GC; which was expected for less pore 
blockage in the GC- Fe3O4 structure. The permeation of progesterone through the GC shell 
itself increased due to the protonation of free amino group at lower pH value. The slight 
change in the pH resulted in uncoiled and more elongated GC networks. In addition, the slight 
reduction in the pH value of the release medium resulted in an increase in the internal osmotic 
pressure and mutual repulsion of the charged amino groups, which yields the uncoiling of the 
GC networks (78) .  
As mentioned above, the overall release rate of progesterone is dependent on its permeation 
through the pores between GC and Fe3O4, and the permeation of progesterone through the GC 
shell itself. However, the overall release rate has been increased at pH value 7.4 because the 
permeation of progesterone through the pores between GC and Fe3O4 is much larger than the 
permeation of progesterone through the GC shell itself.  
3.11 Conclusions 
Polymeric-metallic hybrid nanoparticles were prepared with different compositions of glycol 
chitosan. Generally, glycol chitosan-coated magnetic nanoparticles samples showed 
significant swelling at pH 6.5 and shrinking at pH 7.4. However, the results of progesterone 
release from glycol chitosan hybrid magnetic nanoparticles showed a reversible 
proportionality with the swelling ratio of Fe3O4- GC nanoparticles. In addition, progesterone 
diffusion through the hybrid nanoparticles was observed to change significantly as the 
environmental pH was slightly changed. Investigation of progesterone release kinetics 
demonstrated that a narrow range change in the pH value yielded an increase in the rate of 
drug diffusion. in addition, testing the metabolic cell activity under the treatment Fe3O4- GC 
showed that the particles have good biocompatibility.  The suggested pH-responsive 
nanoparticles demonstrated a good candidate for controlled drug delivery. In addition, the 
114 
 
presence of a magnetic core gives a prospect that other stimuli, such as exposure to an 
externally applied magnetic field, could provide targeted delivery. 
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CHAPTER 4  
Conclusion and recommendations  
This thesis describes an innovative way to form hybrid polymeric-metallic superparamagnetic 
nanoparticles (SPIONS-GC). It addresses their great potential to become a controlled targeted 
drug delivery system in hormonal therapy for breast cancer patients. More specifically, 
magnetic magnetite nanoparticles were produced by a modified co-precipitation method. 
Particles were then loaded with progesterone and coated with a novel polymer, glycol 
chitosan. A comprehensive literature review is presented in chapter 2 with detailed focus on 
polymer types used to surface modify magnetic nanoparticles and their drug delivery 
applications.  
The experimental paper in chapter three studied the preparation of SPION-GC with different 
polymer coating compositions. It presented an extensive study of its physical characterization 
techniques, cytotoxicity cell study, drug encapsulation for controlled progesterone release, and 
mathematical modeling. Drug encapsulation was optimized to control nano-carrier release and 
to prolong its action duration. Release kinetics was analyzed by mathematical fitting, where 
results showed that peppas model was the best-correlated model, indicating the diffusional 
drug release mechanism from the hybrid matrix. In addition, the study highlights the 
capability to control drug release through alteration of environmental pH. It demonstrated that 
swelling of GC at lower pH and its shrinking at higher pH in a small change range can 
significantly trigger progesterone release. It is important to note, however, that the release 
pattern was the same at both environments, where an initial burst effect is noticed followed by 
a sustained release profile for 15 days.  
 
The promising results shown in this thesis open many doors for future research on SPION-
GC. Regarding drug delivery for breast cancer, it would be ideal to include a 
chemotherapeutic drug in addition to the hormonal therapy in the produced polymeric-metallic 
nanoparticles to mimic clinical therapy. Merging two therapeutics will probably enhance 
cancer treatment and build more efficient nanocarriers. Moreover, active targeting can be 
incorporated to offer a much more controlled delivery. This can be accomplished by further 
surface modification via conjugation of mediated ligands such as folic acid, which can 
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selectively target folate receptors that are over expressed by breast cancer cells. Also, since 
the proposed nanoparticles exhibit superparamagnetic properties, adding an external stimuli 
could be beneficial, such an external magnetic field, to allow for magnet-induced guidance to 
cancer sites. With regards to the in vitro drug release, it would be best to test the hybrid 
polymeric-metallic on breast cancer cell to prove that these particles can in fact suppress their 
growth, and this will be ideally tested before and after the addition of dual-drug therapy. 
Furthermore, the ability to better control the initial burst effect can be investigated on to 
optimize it according to therapeutic effectiveness and lag time for nanoparticles to reach the 
desired site. Additionally, it is suggested to conduct an in vivo drug release test in buffer, and 
that will also investigate magnetic targeting more accurately. Generally, the developed 
biocompatible nano-carrier gives a great initiative for further research in controlled drug 
delivery and targeted localized delivery.  
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